Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — INTERLINK ELECTRONICS INC

Accession: 0001104659-26-127061

Filed: 2026-11-13

Period: 2026-11-13

CIK: 0000828146

SIC: 3577 (COMPUTER PERIPHERAL EQUIPMENT, NEC)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — tm2629702d1_8k.htm (Primary)

EX-1.1 — EXHIBIT 1.1 (tm2629702d1_ex1-1.htm)

EX-5.1 — EXHIBIT 5.1 (tm2629702d1_ex5-1.htm)

GRAPHIC (tm2629702d1_ex5-1img01.jpg)

GRAPHIC (tm2629702d1_ex5-1img02.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2629702d1_8k.htm · Sequence: 1

false

0000828146

0000828146

2026-11-13

2026-11-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT

REPORT

PURSUANT TO SECTION

13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 13, 2026

INTERLINK ELECTRONICS, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada

001-37659

77-0056625

(State or Other Jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification No.)

48389 Fremont Boulevard, Suite 110

Fremont, California

94538

(Address of Principal Executive Offices)

(Zip Code)

(510) 244-0424

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value

LINK

The NASDAQ Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

On November 13, 2026, Interlink

Electronics, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”)

with A.G.P/Alliance Global Partners, as sales agent (“AGP”), pursuant to which the Company may offer and sell from time to

time, through AGP, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an

aggregate offering price of up to $7,200,000.

The Common Stock will

be offered and sold pursuant to an existing shelf registration statement on Form S-3 filed by the Company with the U.S. Securities

and Exchange Commission, which became effective on December 23, 2024 (File No. 333-283879). A prospectus supplement relating

to the offer and sale of the Common Stock pursuant to the Sales Agreement was also filed with the Securities and Exchange Commission on

November 13, 2026.

Upon

delivery of a transaction notice and subject to the terms and conditions of the Sales Agreement, AGP may

sell the Common Stock by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) of

the Securities Act of 1933, as amended. AGP is not required to purchase any shares of Common

Stock from the Company or sell any specific number of shares of Common Stock or dollar amount of Common Stock but will use its commercially

reasonable efforts consistent with its normal trading and sales practices and appliable state and federal law, rules and regulations

and the rules of the Nasdaq Stock Market, LLC to sell shares of our Common Stock pursuant to the Sales Agreement as directed by the

Company. The Company will pay AGP a commission equal to three percent (3.0%) of the gross

sales price of the shares of Common Stock sold through AGP under the Sales Agreement, and

has also provided AGP with certain indemnification and contribution rights.

The Company intends to

use the net proceeds from the offering for working capital, capital expenditures and other general corporate purposes, and for product

development. The Company also may use a portion of the proceeds to finance potential acquisitions and investments in companies or products

that are complementary to its business if and when suitable opportunities arise; however, the Company currently has no commitments or

agreements with respect to any such transactions.

The

foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales

Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein

by reference. A copy of the legal opinion and consent of Stubbs Alderton & Markiles, LLP relating to the legality of the

shares of Common Stock that may be issued pursuant to the Sales Agreement is attached as Exhibit 5.1 to

this Current Report on Form 8-K.

This Current Report on

Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall

there be any offer, solicitation, or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful

prior to registration or qualification under the securities laws of any such jurisdiction.

2

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Description

1.1

At-The-Market Issuance Sales Agreement, dated as of November 13, 2026, by and between Interlink Electronics, Inc.

and A.G.P./Alliance Global Partners.

5.1

Opinion of Stubbs Alderton & Markiles, LLP regarding legality of the shares.

23.1

Consent of Stubbs Alderton & Markiles, LLP (included in Exhibit 5.1).

104

Cover Page Interactive Data File for this Current Report on Form 8-K (formatted as Inline XBRL and contained in Exhibit 101)

3

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 13, 2026

INTERLINK ELECTRONICS, INC.

By:

/s/ Ryan J. Hoffman

Ryan J. Hoffman

Chief Financial Officer

4

EX-1.1 — EXHIBIT 1.1

EX-1.1

Filename: tm2629702d1_ex1-1.htm · Sequence: 2

Exhibit 1.1

INTERLINK

ELECTRONICS, INC

Up to $7,200,000

of Common Stock

AT-THE-MARKET

ISSUANCE SALES AGREEMENT

November 13,

2026

A.G.P./Alliance Global Partners

590 Madison Avenue, 28th Floor

New York, NY 10022

Ladies and Gentlemen:

Interlink Electronics, Inc.,

a Nevada corporation (the “Company”), proposes to issue and sell through A.G.P./Alliance Global Partners, as

selling agent (the “Agent”), shares of common stock, par value $0.001 per share, of the Company (the “Common

Stock”), having an aggregate offering price of up to US$7,200,000 of Common Stock (the Common Stock subject to this At-The-Market

Issuance Sales Agreement (this “Agreement”) being referred to herein as the “Shares”)

on terms set forth herein and subject to the limitations set forth in Section 2(a) hereof. The Shares consist entirely

of authorized but unissued shares of Common Stock to be issued and sold by the Company.

The Company hereby confirms

its agreement with the Agent with respect to the sale of the Shares.

1. Representations and

Warranties of the Company.

(a) The Company represents

and warrants to, and agrees with, the Agent as follows as of the date of this Agreement, each Settlement Date, each Time of Sale, each

time a Transaction Notice is delivered and each Bringdown Date (except that such representations and warranties shall be deemed to relate

to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares on such date):

(i) A registration statement

on Form S-3 (File No. 333-283879) (the “registration statement”) was initially declared effective

by the U.S. Securities and Exchange Commission (the “Commission”) on December 23, 2024, and is currently

effective, under the Securities Act of 1933, as amended (the “Securities Act of 1933”), and the rules and

regulations promulgated thereunder (the “Rules and Regulations” and collectively with the Securities Act

of 1933, the “Securities Act”); since the date of effectiveness of the registration statement, no additional

or supplemental information was requested by the Commission; no stop order of the Commission preventing or suspending the use of any Base

Prospectus (as defined below), the Prospectus Supplement (as defined below), the Prospectus (as defined below) or any Permitted Free Writing

Prospectus (as defined below), or the effectiveness of the registration statement, has been issued, and no proceedings for such purpose

have been instituted or, to the Company’s knowledge, are contemplated by the Commission. Except where the context otherwise requires,

“Registration Statement,” as used herein, means the registration statement, as amended at the time of such registration

statement’s effectiveness for purposes of Section 11 of the Securities Act, as such section applies to the Agent, including

(1) all documents filed as a part thereof or incorporated or deemed to be incorporated by reference therein, (2) any information

contained or incorporated by reference in a prospectus filed with the Commission pursuant to Rule 424(b) under the Securities

Act, to the extent such information is deemed, pursuant to Rule 430B or Rule 430C under the Securities Act, to be part of the

registration statement at such time, and (3) any registration statement filed to register the offer and sale of Shares pursuant to

Rule 462(b) under the Securities Act (the “462(b) Registration Statement”). Except where the

context otherwise requires, “Base Prospectus,” as used herein, means the prospectus filed as part of the Registration

Statement, together with any amendments or supplements thereto as of the date of this Agreement. Except where the context otherwise requires,

“Prospectus Supplement,” as used herein, means the most recent prospectus supplement relating to the Shares,

filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act and in accordance with the terms of

this Agreement. Except where the context otherwise requires, “Prospectus,” as used herein, means the Prospectus

Supplement together with the Base Prospectus attached to or used with the Prospectus Supplement, as may be amended or supplemented from

time to time. “Permitted Free Writing Prospectus,” as used herein, means the documents, if any, listed on Schedule

A attached hereto and, after the date hereof, any “issuer free writing prospectus” as defined in Rule 433 of the

Securities Act, that is expressly agreed to by the Company and the Agent in writing to be a Permitted Free Writing Prospectus. Any reference

herein to the Registration Statement, the Base Prospectus, the Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus

shall be deemed to refer to and include the documents, if any, incorporated by reference, or deemed to be incorporated by reference, therein

pursuant to Item 12 of Form S-3 (the “Incorporated Documents”), including, unless the context otherwise

requires, the documents, if any, filed as exhibits to such Incorporated Documents. For purposes of this Agreement, all references to the

Registration Statement, the Rule 462(b) Registration Statement, the Base Prospectus, the Prospectus Supplement, the Prospectus,

or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic

Data Gathering, Analysis and Retrieval System (“EDGAR”). The Company has prepared a Prospectus Supplement specifically

related to the Shares, which shall be filed with the Commission prior to the delivery of any Transaction Notice. All references in this

Agreement to financial statements and schedules and other information which is “described,” “contained,” “included”

or “stated” in the Registration Statement, the Base Prospectus, the Prospectus Supplement, the Prospectus or any Permitted

Free Writing Prospectus (or other references of like import) shall be deemed to mean and include all such financial statements and schedules

and other information which is incorporated by reference in or otherwise deemed by the Rules and Regulations to be a part of or included

in the Registration Statement, the Base Prospectus, the Prospectus Supplement, the Prospectus or Permitted Free Writing Prospectus as

the case may be. Any reference herein to the terms “amend,” “amendment” or “supplement”

with respect to the Registration Statement, any Base Prospectus, the Prospectus, the Prospectus Supplement or any Permitted Free Writing

Prospectus shall be deemed to refer to and include the filing of any document under the Securities Exchange Act of 1934, as amended, and

the rules and regulations thereunder (collectively, the “Exchange Act”) on or after the initial effective

date of the Registration Statement, or the date of such Base Prospectus, the Prospectus, the Prospectus Supplement or such Permitted Free

Writing Prospectus, if any, as the case may be, and incorporated or deemed to be incorporated therein by reference pursuant to Item 12

of Form S-3. “Time of Sale” means each time a Share is purchased pursuant to this Agreement.

(ii) (A) The Registration

Statement complied when it became effective, complies as of the date hereof, and will comply upon the effectiveness of any amendment thereto

and at each Time of Sale, each Settlement Date (as defined below) and at the time of delivery of each Transaction Notice, and each Bringdown

Date, as applicable, in all material respects, with the requirements of the Securities Act; at all times during which a prospectus is

required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or

any similar rule) in connection with any sale of Shares (the “Prospectus Delivery Period”); the Registration

Statement, as may be amended, will comply, in all material respects, with the requirements of the Securities Act; the conditions to the

use of Form S-3 in connection with the offering and sale of the Shares as contemplated hereby (the “Offering”)

have been satisfied, the Registration Statement meets, and the Offering complies with, the requirements of Rule 415 under the Securities

Act (including, without limitation, Rule 415(a)(5)); the Registration Statement did not, as of the time of its effectiveness and

as of the date hereof, and will not, as of the effective date of any amendment thereto, at each Time of Sale, if any, and at all times

during a Prospectus Delivery Period, contain an untrue statement of a material fact or omit to state a material fact required to be stated

therein or necessary to make the statements therein not misleading. There is no stop order suspending effectiveness of the Registration

Statement.

(B) The Prospectus, as

of the date of the Prospectus Supplement, as of the date hereof (if filed with the Commission on or prior to the date hereof), at each

Settlement Date, Time of Sale and at the time of delivery of each Transaction Notice, and each Bringdown Date (as applicable), and at

all times during a Prospectus Delivery Period, complied, complies or will comply, in all material respects, with the requirements of the

Securities Act; and the Prospectus, and each supplement thereto, as of their respective dates, at each Settlement Date or Time of Sale

(as applicable), and at all times during a Prospectus Delivery Period, did not and will not include an untrue statement of a material

fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which

they were made, not misleading.

(C) Each Permitted Free

Writing Prospectus, if any, as of its date and as of each Settlement Date, Time of Sale and at the time of delivery of each Transaction

Notice, and each Bringdown Date (as applicable), and at all times during a Prospectus Delivery Period (when taken together with the Prospectus

at such time) will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the

statements therein, in the light of the circumstances under which they were made, not misleading.

The representations and warranties

set forth in subparagraphs (A), (B) and (C) above shall not apply to any statement contained in the Registration Statement,

any Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus in reliance upon and in conformity with information concerning

the Agent that is furnished in writing by or on behalf of the Agent expressly for use in the Registration Statement, such Base Prospectus,

the Prospectus Supplement, the Prospectus or such Permitted Free Writing Prospectus, if any, it being understood and agreed that only

such information furnished by the Agent as of the date hereof consists of the information described in Section 5(b)(ii).

2

(iii) Prior to the execution

of this Agreement, the Company has not, directly or indirectly, offered or sold any Shares by means of any “prospectus” (within

the meaning of the Securities Act) or used any “prospectus” (within the meaning of the Securities Act) in connection with

the Offering, in each case other than the Base Prospectus, the Prospectus Supplement, Prospectus or any Permitted Free Writing Prospectus;

the Company has not, directly or indirectly, prepared, used or referred to any Permitted Free Writing Prospectus except in compliance

with Rules 164 and 433 under the Securities Act; assuming that a Permitted Free Writing Prospectus, if any, is sent or given after

the Registration Statement was filed with the Commission (and after such Permitted Free Writing Prospectus, if any, was, if required pursuant

to Rule 433(d) under the Securities Act, filed with the Commission), the Company will satisfy the provisions of Rule 164

or Rule 433 necessary for the use of a free writing prospectus (as defined in Rule 405) in connection with the Offering; the

conditions set forth in one or more of subclauses (i) through (iv), inclusive, of Rule 433(b)(1) under the Securities Act

are satisfied, and the registration statement relating to the Offering, as initially filed with the Commission, includes a prospectus

that, other than by reason of Rule 433 or Rule 431 under the Securities Act, satisfies the requirements of Section 10 of

the Securities Act; neither the Company nor the Agent, nor any of the other designees, is disqualified, by reason of subsection (f) or

(g) of Rule 164 under the Securities Act, from using, in connection with the Offering, “free writing prospectuses”

(as defined in Rule 405 under the Securities Act) pursuant to Rules 164 and 433 under the Securities Act; the Company is not

an “ineligible issuer” (as defined in Rule 405 under the Securities Act) as of the eligibility determination date for

purposes of Rules 164 and 433 under the Securities Act with respect to the offering of the Shares contemplated by the Registration

Statement; the parties hereto agree and understand that the content of any and all “road shows” (as defined in Rule 433

under the Securities Act) related to the Offering is solely the property of the Company.

(iv) Each Permitted Free

Writing Prospectus, as of its issue date, each Time of Sale, each Settlement Date and at the time of delivery of each Transaction Notice,

and each Bringdown Date, occurring after such issue date and at all subsequent times through the Prospectus Delivery Period or until any

earlier date that the Company notified or notifies the Agent as described in Section 3(c)(iii), did not, does not and will

not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement,

any Base Prospectus, Prospectus Supplement, or the Prospectus. The foregoing sentence does not apply to statements in or omissions from

any Permitted Free Writing Prospectus based upon and in conformity with written information furnished to the Company by the Agent specifically

for use therein, it being understood and agreed that only such information furnished by the Agent as of the date hereof consist of the

information described in Section 5(b)(ii).

(v) The consolidated

financial statements of the Company and the Subsidiaries (as defined below), together with the related notes and supporting schedules,

set forth or incorporated by reference in the Registration Statement and the Prospectus comply in all material respects with the requirements

of the Securities Act and the Exchange Act and fairly present in all material respects the financial condition of the Company and the

Subsidiaries, as a whole, as of the dates indicated and the results of operations and changes in cash flows for the periods therein specified

in conformity with U.S. generally accepted accounting principles consistently applied throughout the periods involved. The selected financial

data and the summary financial information included in the documents in the Registration Statement and in the Prospectus, as applicable,

constitute a fair summary of the information purported to be summarized and have been compiled on a basis consistent with that of the

audited financial statements included in the Registration Statement. No other financial statements or supporting schedules are required

to be included or incorporated by reference in the Registration Statement or the Prospectus under the Securities Act except as so included

or incorporated by reference. All disclosures contained in the Registration Statement or the Prospectus or incorporated by reference therein

regarding “non-GAAP financial measures” (as such term is defined by the applicable rules and regulations of the Commission)

comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act to the extent applicable. To the Company’s

knowledge, LMHS, P.C., which has expressed its opinion with respect to the audited financial statements for the fiscal years ended December 31,

2025 and 2024 and which has reviewed the unaudited financial statements for each of the three months ended March 31, 2026, the three

and six months ended June 30, 2026 and the three and nine months ended September 30, 2026 (the audited financial statements

for the fiscal years ended December 31, 2025 and 2024 and the unaudited financial statements for each of the three months ended March 31,

2026, the three and six months ended June 30, 2026 and the three and nine months ended September 30, 2026, collectively, the

“Incorporated Financial Statements”), filed as a part of the Registration Statement and included in the Registration

Statement and the Prospectus, is a registered public accounting firm within the meaning of the Securities Act, and LMHS, P.C., in the

performance of its work for the Company, has not been in violation of the auditor independence requirements of the Sarbanes-Oxley Act

of 2002 (the “Sarbanes-Oxley Act”). There are no transactions, arrangements and other relationships between

and/or among the Company, and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but

not limited to, any structural finance, special purpose or limited purpose entity (each, an “Off-Balance Sheet Transaction”)

that could reasonably be expected to affect materially the Company’s liquidity or the availability of or requirements for its capital

resources, including those Off Balance Sheet Transactions described in the Commission’s Statement about Management’s Discussion

and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), and are required to be described

in the Prospectus, which have not been described as required.

3

(vi) The Company and

each of its Subsidiaries has been duly organized and is validly existing as a corporation under the laws of its jurisdiction of incorporation.

The Company and each of the Subsidiaries has full corporate power and authority to own its respective properties and conduct its respective

businesses as currently being carried on and as described in the Registration Statement and the Prospectus, and is duly qualified to do

business as a foreign corporation in good standing in each jurisdiction in which it owns or leases real property or in which the conduct

of its business makes such qualification necessary and in which the failure to so qualify would have a material adverse effect upon the

results of operations, business, management, properties, prospects, conditions (financial or otherwise) or operations, of the Company

and the Subsidiaries, either individually or taken as a whole (“Material Adverse Effect”). The Company does

not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21.1

to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

(vii) Except as disclosed

in the Prospectus, subsequent to the dates as of which information is given in the Prospectus, the Company (including its Subsidiaries

on a consolidated basis) has not sustained any material loss or interference with its business from fire, explosion, flood or other calamity,

whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree; incurred any material

liabilities or obligations, direct or contingent, or entered into any material transactions, or declared or paid any dividends or made

any distribution of any kind with respect to the capital stock of the Company other than monthly cash dividends on the Company’s

8.0% Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Convertible Preferred Stock”);

and there has not been any change in the capital stock of the Company, or issuance of options, warrants, convertible securities or other

rights to purchase the capital stock of the Company, or any material change in the short-term or long-term debt of the Company (other

than as a result of the exercise of any currently outstanding stock options and warrants that are disclosed in the Prospectus), or any

Material Adverse Effect or any development that would reasonably be expected to result in a Material Adverse Effect. Since the date of

the latest balance sheet presented in the Registration Statement and the Prospectus, neither the Company nor any Subsidiary has entered

into any transactions, including any acquisition or disposition of any business or asset, which are material to the Company and the Subsidiaries

taken as a whole, except for transactions which are disclosed in the Registration Statement and the Prospectus.

(viii) Except as set

forth in the Prospectus, there is not pending or, to the knowledge of the Company, threatened or contemplated, any action, suit or proceeding

to which the Company or any of its Subsidiaries or of which any property or assets of the Company or any of its Subsidiaries is the subject

before or by any court or governmental agency, authority or body, or any arbitrator or mediator, which, individually or in the aggregate,

would reasonably be expected to result in any Material Adverse Effect.

(ix) There are no statutes,

regulations, contracts or documents that are required to be described in the Registration Statement and the Prospectus or be filed as

exhibits to the Registration Statement by the Securities Act that have not been so described or filed.

4

(x) The Company has all

corporate power and authority to execute, deliver and perform its obligations under this Agreement. This Agreement has been duly authorized,

executed and delivered by the Company, and constitutes a valid, legal and binding obligation of the Company, enforceable against the Company

in accordance with its terms, except as rights to indemnity hereunder may be limited by federal or state securities laws and except as

such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally

and subject to general principles of equity. The issue and sale of the Shares, the execution, delivery and performance of this Agreement

and the consummation of the transactions herein contemplated will not result in a breach or violation of any of the terms and provisions

of, or constitute a default under, (i) any law, rule or regulation to which the Company or any of its Subsidiaries is subject,

(ii) any agreement or instrument to which the Company or any of its Subsidiaries or by which it is bound or to which any of its property

is subject, (iii) the Company’s articles of incorporation or bylaws, each as amended to date, or the organizational documents

of any of its Subsidiaries, or (iv) any order, rule, regulation or decree of any court or governmental agency or body having jurisdiction

over the Company or any of its Subsidiaries or any of its properties, except, in the case of clauses (i), (ii) and (iv), for such

breaches, violations or defaults that would not reasonably be expected to result in a Material Adverse Effect; no consent, approval, authorization

or order of, or filing with, any court or governmental agency or body is required for the execution, delivery and performance of this

Agreement or for the consummation of the transactions contemplated hereby and thereby, including the issuance or sale of the Shares by

the Company, except for such consents, approvals, authorizations, orders or filings as have been obtained or made or as may be required

under the Securities Act or state securities or blue sky laws; and the Company has and will have full power and authority to enter into

this Agreement and to authorize, issue and sell the Shares as contemplated hereby and thereby.

(xi) All of the issued

and outstanding shares of capital stock of the Company, including the outstanding Common Stock are duly authorized and validly issued,

fully paid and nonassessable, have been issued in compliance with all applicable foreign, federal and state securities laws, were not

issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities that have not been

waived in writing, and the holders thereof are not subject to personal liability by reason of being such holders; all of the issued and

outstanding shares of capital stock of each of the Subsidiaries are duly authorized and validly issued, fully paid and nonassessable,

and are owned by the Company, directly or through wholly-owned Subsidiaries, free and clear of any security interest, mortgage, pledge,

lien, encumbrance, claim or equity except for those arising under any credit facility or loan agreement to which the Company or any of

its Subsidiaries is a party or their assets are bound as disclosed in the Registration Statement and the Prospectus, have been issued

in compliance with all applicable foreign, federal and state securities laws, were not issued in violation of or subject to any preemptive

rights or other rights to subscribe for or purchase securities that have not been waived in writing, and the holders thereof are not subject

to personal liability by reason of being such holders; the Shares which may be sold under this Agreement by the Company have been duly

authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement will have been validly issued and will

be fully paid and nonassessable, and the holders thereof will not be subject to personal liability solely by reason of being such holders;

and the capital stock of the Company, including the Common Stock, conforms in all material respects to the description thereof in the

Registration Statement and the Prospectus. Except as otherwise stated in the Registration Statement and the Prospectus, there are no preemptive

rights or other rights to subscribe for or to purchase, or any restriction upon the voting or transfer of, any Common Stock pursuant to

the Company’s articles of incorporation, or any agreement or other instrument to which the Company is a party or by which the Company

is bound. Except as described in the Registration Statement and the Prospectus, there are no options, shares of preferred stock, restricted

stock units, stock appreciation rights, warrants, convertible securities, agreements, contracts or other rights in existence to purchase

or acquire from the Company any shares of the capital stock of the Company. The Company has an authorized and outstanding capitalization

as set forth in the Registration Statement and the Prospectus as of the dates set forth therein and the issued and outstanding securities

conform in all material respects to the descriptions thereof contained in the Registration Statement and the Prospectus.

(xii) The Company and

each of its Subsidiaries holds, and is operating in compliance with all grants, authorizations, licenses, permits, consents, certificates

and orders of any governmental or self-regulatory body required for the conduct of its respective businesses and all such grants, authorizations,

licenses, permits, consents, certifications and orders are valid and in full force and effect, except for such noncompliance or failures

to be in full force and effect that would not reasonably be expected to result in a Material Adverse Effect; and neither the Company nor

any of its Subsidiaries has received notice of any revocation or modification of any such grant, authorization, license, permit, consent,

certification or order or has reason to believe that any such grant, authorization, license, permit, consent, certification or order will

not be renewed in the ordinary course; and the Company and each of its Subsidiaries is in compliance with all applicable federal, state,

local and foreign laws, regulations, orders and decrees, except for such noncompliance that would not reasonably be expected to result

in a Material Adverse Effect. No approval, authorization, consent or order of or filing with any foreign, federal, state or local governmental

or regulatory commission, board, body, authority or agency is required in connection with the issuance and sale of the Shares or the consummation

by the Company of the transactions contemplated hereby, other than (i) registration of the Shares under the Securities Act, (ii) any

necessary qualification under the securities or blue sky laws of the various jurisdictions in which the Shares are being offered by the

Agent or other designees, (iii) the filing of any reports under the Exchange Act, (iv) such approvals as may be required by

the Conduct Rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”), (v) approval

of the listing of the Shares by The Nasdaq Stock Market LLC (“Nasdaq”) or (vi) such approvals as have been

obtained or made as of the Time of Sale.

5

(xiii) The Company and

each of its Subsidiaries has good and marketable title to all property (whether real or personal) described in the Registration Statement

and the Prospectus as being owned by it, in each case free and clear of all liens, claims, security interests, other encumbrances or defects

except such as are described in the Registration Statement and the Prospectus, except as would not materially impair the use or value

thereof. The property held under lease by the Company and each of its Subsidiaries is held by it under valid, subsisting and enforceable

leases with only such exceptions with respect to any particular lease as do not interfere in any material respect with the conduct of

the business of the Company or such Subsidiary.

(xiv) The Company and

each of its Subsidiaries owns, possesses, or can acquire on reasonable terms, all Intellectual Property (as defined below) necessary for

the conduct of their respective businesses as now conducted or as described in the Registration Statement and the Prospectus to be conducted.

Except as would not result in a Material Adverse Effect, (A) there are no rights of third parties to any such Intellectual Property

owned by the Company, except as described in the Registration Statement or Prospectus; (B) to the knowledge of the Company, there

is no infringement, misappropriation or violation by third parties of any such Intellectual Property; (C) there is no pending or,

to the knowledge of the Company, threatened, action, suit, proceeding or claim by others challenging the Company’s or any Subsidiary’s

rights in or to any such Intellectual Property and the Company is unaware of any fact that would form a reasonable basis for any such

claim; (D) the Intellectual Property owned by the Company and each of the Subsidiaries, and to the knowledge of the Company, the

Intellectual Property licensed to the Company and each of the Subsidiaries, has not been adjudged invalid or unenforceable, in whole or

in part, and there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging

the validity or scope of any such Intellectual Property and the Company is unaware of any fact that would form a reasonable basis for

any such claim; (E) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others

that the Company or any of its Subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary

rights of others, and neither the Company nor any of the Subsidiaries has received any written notice of such claim; and (F) to the

Company’s knowledge, no employee of the Company or any of its Subsidiaries is in, or since January 1, 2025 has been in, violation

of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation

agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates

to such employee’s employment with the Company or any of its Subsidiaries or actions undertaken by the employee while employed with

the Company or any of its Subsidiaries. “Intellectual Property” shall mean all patents, patent applications,

trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, domain names,

technology, know-how and other intellectual property.

(xv) Neither the Company

nor any of its Subsidiaries is (A) in violation of its articles of incorporation, or similar organizational documents, or (B) in

breach of or otherwise in default, and no event has occurred which, with notice or lapse of time or both, would constitute such a default

in the performance of any material obligation, agreement or condition contained in any bond, debenture, note, indenture, loan agreement,

mortgage, deed of trust or any other material contract, lease or other instrument to which it is subject or by which any of them may be

bound, or to which any of the material property or assets of the Company or any of its Subsidiaries is subject (collectively, the “Material

Contracts”); or (C) in violation of any law or statute or any judgment, order, rule or regulation of any court

or arbitrator or governmental or regulatory authority, except in the case of (B) and (C) above, as could not, individually or

in the aggregate, reasonably be expected to result in a Material Adverse Effect.

6

(xvi) The Company and

each of the Subsidiaries has timely filed all applicable federal, state, local, foreign and other income and franchise tax returns required

to be filed and are not in default in the payment of any taxes which were payable pursuant to said returns or any assessments with respect

thereto. The provisions for taxes payable, if any, shown on the financial statements included or incorporated by reference in the Registration

Statement and the Prospectus are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including

the dates of such consolidated financial statements, and there are no tax liens against the assets, properties or business of the Company

or any of its Subsidiaries. There is no pending dispute with any taxing authority relating to any of such returns, and the Company has

no knowledge of any proposed liability for any tax to be imposed upon the properties or assets of the Company or any of its Subsidiaries

for which there is not an adequate reserve reflected in the Company’s financial statements included in the Registration Statement.

There are no documentary, stamp or other issuance or transfer taxes or duties or similar fees or charges under U.S. federal law or the

laws of any U.S. state, required to be paid in connection with the execution and delivery of this Agreement or the issuance, sale and

delivery by the Company of the Shares.

(xvii) The Company has

not distributed and will not distribute any prospectus or other offering material in connection with the Offering other than the Registration

Statement and the Prospectus or other materials permitted by the Securities Act to be distributed by the Company; provided, however, that

the Company has not made and will not make any offer relating to the Shares that would constitute a “free writing prospectus”

as defined in Rule 405 under the Securities Act, except in accordance with the provisions of Section 3(o) of this

Agreement.

(xviii) The issuance

and sale of the Shares as contemplated in this Agreement does not contravene the rules and regulations of Nasdaq. The Common Stock

is registered pursuant to Section 12(b) of the Exchange Act and is listed on Nasdaq and the Company has taken no action designed

to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock

from Nasdaq nor, except as disclosed in the Registration Statement or the Prospectus, has the Company received any notification that the

Commission or Nasdaq is contemplating terminating such registration or listing. The Company has complied in all material respects with

the applicable requirements of Nasdaq for maintenance of the listing of the Common Stock on Nasdaq. The Company has filed an application

to include the Shares on Nasdaq. The Company has no intention to delist the Common Stock from Nasdaq or to deregister the Common Stock

under the Exchange Act, in either case, at any time during the period commencing on the date of this Agreement through and including the

90th calendar day after the termination of this Agreement.

(xix) The Company has

no subsidiaries other than those described in the Prospectus and the Incorporated Documents (collectively, the “Subsidiaries”).

Other than with respect to the Subsidiaries, the Company does not own, directly or indirectly, any shares of stock or any other equity

or long-term debt securities of any other corporation or have any equity interest in any other corporation, partnership, joint venture,

association, trust or other entity except as described in the Registration Statement or Prospectus.

(xx) The Company and

each of its Subsidiaries have established and maintain systems of internal accounting controls sufficient to provide reasonable assurances

that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions

are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and

to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific

authorization; and (D) amounts reflected on the Company’s consolidated balance sheet for assets are compared with existing

assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the Registration

Statement and the Prospectus, since the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31,

2025 with the Commission, there has been (i) no material weakness identified to the Company’s board of directors (or committee

thereof) in the Company’s internal control over financial reporting (whether or not remediated) and (ii) no change in the Company’s

internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s

internal control over financial reporting.

7

(xxi) Except as described

in the Registration Statement and the Prospectus, the Company and each of the Subsidiaries: (A) is and at all times since January 1,

2025 has been in compliance with all United States (federal, state and local) and foreign statutes, rules, regulations, treaties, or guidance

applicable to the Company or the Subsidiaries (“Applicable Laws”), except where the failure to be in compliance

would not reasonably be expected to result in a Material Adverse Effect; (B) since January 1, 2025 has not received any notice

of adverse finding, warning letter, untitled letter or other correspondence or notice from any Governmental Authority (as defined below)

alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits

and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) since

January 1, 2025 has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration

or other action from any Governmental Authority or third party alleging that any product operation or activity is in violation of any

Applicable Laws or Authorizations and has no knowledge that any such Governmental Authority or third party intends to assert any such

claim, litigation, arbitration, action, suit, investigation or proceeding; (D) since January 1, 2025 has not received notice

that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations

and the Company has no knowledge that any such Governmental Authority is considering such action; and (E) has filed, obtained, maintained

or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments

as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims,

submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent

submission). “Governmental Authority” means any federal, provincial, state, local, foreign or other governmental

or quasi-governmental agency or body or any other type of regulatory authority or body, including, without limitation, Nasdaq. The aggregate

of all pending legal or governmental proceedings to which the Company or any Subsidiary is a party or of which any of their respective

property or assets is the subject which are not described in the Registration Statement and the Prospectus, including ordinary routine

litigation incidental to the business, would not result in a Material Adverse Effect.

(xxii) Other than as

contemplated by this Agreement, the Company has not incurred any liability for any finder’s or broker’s fee or agent’s

commission in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby.

The Company has not entered into any other sales agency agreements or other similar arrangements with any agent or any other representative

in respect of “at the market” offerings of the Shares in accordance with Rule 415 under the Securities Act.

(xxiii) The Company and

each of the Subsidiaries carries, or is covered by, insurance in such amounts and covering such risks the Company reasonably believes

are adequate for the conduct of its respective business and the value of its properties and as is customary for companies engaged in similar

businesses in similar industries; all policies of insurance and any fidelity or surety bonds insuring the Company, each of its Subsidiaries

and their respective businesses, assets, employees, officers and directors are in full force and effect; the Company and each of its Subsidiaries

is in compliance with the terms of such policies and instruments in all material respects; there are no claims by the Company or any of

the Subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation

of rights clause; neither the Company nor any of the Subsidiaries has been refused any insurance coverage sought or applied for; and the

Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or

to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material

Adverse Effect.

(xxiv) The Company is

not (and is not an affiliate of), and immediately after receipt of payment for the Shares, will not be (and will not be an affiliate of),

an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company currently intends

to conduct its business in a manner so that it will not become subject to the Investment Company Act of 1940, as amended.

(xxv) The Incorporated

Documents, at the time they were or hereinafter are filed with the Commission, conformed and will conform in all material respects to

the requirements of the Securities Act and the Exchange Act, and were filed on a timely basis with the Commission and no Incorporated

Document contained or will contain an untrue statement of a material fact or omitted to state a material fact necessary to make the statements

therein, in the light of the circumstances under which they were made, not misleading; provided, that, no representation is made herein

regarding the representations, warranties and covenants, or any descriptions thereof, contained in any agreements or documents included

as exhibits to the Incorporated Documents. There is no material document required to be described in the Registration Statement or the

Prospectus or to be filed as an exhibit to the Registration Statement which was not described or filed as required. All material agreements

of the Company and all agreements governing or evidencing any and all related party transactions have been filed with the Commission to

the extent required and applicable under the Exchange Act. Neither the Company nor any Subsidiaries has sent or received any communication

regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in the Registration Statement

and the Prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement or any Incorporated Document,

and no such termination or non-renewal has been threatened by the Company or any of its Subsidiaries or, to the Company’s knowledge,

any other party to any such contract or agreement. Any descriptions of the terms of any of the foregoing contracts and agreements that

are contained in the Registration Statement and the Prospectus are accurate and complete in all material respects.

8

(xxvi) The Company is

in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act and the rules and regulations of

the Commission thereunder.

(xxvii) Except as described

in the Registration Statement and the Prospectus, the Company has established and maintains disclosure controls and procedures (within

the meaning of Rule 13a-15(e) of the Exchange Act) and such controls and procedures are designed to ensure that information

required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and

reported within the time periods specified in the rules and forms of the Commission and that such information is accumulated and

communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to

allow timely decisions regarding required disclosure. The Company has utilized such controls and procedures in preparing and evaluating

the disclosures in the Registration Statement and the Prospectus.

(xxviii) Neither the

Company, the Subsidiaries, nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or

any Subsidiary, has taken any action directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices

Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation,

making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise

to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything

of value to any “Foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof

or any candidate for foreign political office, in contravention of the FCPA, and the Company and each of its Subsidiaries has conducted

its business in compliance with the FCPA and has instituted and maintains policies and procedures designed to ensure, and which are reasonably

expected to continue to ensure, continued compliance therewith.

(xxix) The Company and

each of its Subsidiaries are and have been at all times in compliance with the money laundering statutes of applicable jurisdictions,

the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced

by applicable governmental agencies (collectively, the “Money Laundering Laws”), and no action, suit or proceeding

by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with

respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(xxx) Neither the Company,

any of its Subsidiaries, nor, to the knowledge of the Company, any director, officer, employee, representative, agent, or affiliate of

the Company or any of its Subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control

of the U.S. Department of the Treasury (“OFAC”); and the Company will not directly or indirectly use the proceeds

of the Offering, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other person

or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

(xxxi) No transaction

has occurred or agreement or understanding entered into between or among the Company or any of its Subsidiaries on the one hand, and any

officer, director or 5% or greater stockholder of the Company or any Subsidiary of the Company or any affiliate or affiliates of any such

officer, director or 5% or greater stockholder that is required to be described that is not so described in the Registration Statement

and the Prospectus. Neither the Company nor any of its Subsidiaries has, directly or indirectly, extended or maintained credit, or arranged

for the extension of credit, or renewed an extension of credit, in the form of a personal loan to or for any of its directors or executive

officers.

9

(xxxii) (a) Neither

the Company nor any of its Subsidiaries is in violation of any applicable international, national, state or local convention, law, regulation,

order, governmental license, convention, treaty (including those promulgated by the International Maritime Organization) or other requirement

relating to pollution or protection of human health or safety (as they relate to exposure to Materials of Environmental Concern (as defined

below)) or protection of the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface

strata) or protection of natural resources, including without limitation, conventions, laws or regulations relating to emissions, discharges,

releases or threatened releases of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum, petroleum

products or other hydrocarbons (collectively, “Materials of Environmental Concern”), or otherwise relating to

the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Materials of Environmental Concern

(collectively, “Environmental Laws”), nor has the Company or any Subsidiary received any written communication,

whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company or any such Subsidiary is

in violation of any Environmental Law or governmental license required pursuant to Environmental Law; except, in each case, as would not,

individually or in the aggregate, have a Material Adverse Effect; (b) there is no claim, action or cause of action filed with a court

or Governmental Authority and no investigation, or other action with respect to which the Company or any Subsidiary has received written

notice alleging potential liability for investigatory costs, cleanup costs, governmental response costs, natural resources damages, property

damages, personal injuries, attorneys’ fees or penalties arising out of, based on or resulting from the presence, or release into

the environment, of any Material of Environmental Concern at any location owned, leased or operated by the Company or any Subsidiary,

now or in the past, or from any vessel owned, leased or operated by the Company or any Subsidiary, now or in the past (collectively, “Environmental

Claim”), pending or, to the knowledge of the Company, threatened against the Company or any Subsidiary or any person or

entity whose liability for any Environmental Claim the Company or any Subsidiary has retained or assumed either contractually or by operation

of law, except as would not, individually or in the aggregate, have a Material Adverse Effect; (c) to the knowledge of the Company,

there are no past or present actions, activities, circumstances, conditions, events or incidents, including, without limitation, the release,

emission, discharge, presence or disposal of any Material of Environmental Concern, that reasonably would be expected to result in a violation

of any Environmental Law, require expenditures to be incurred pursuant to Environmental Law, or form the basis of an Environmental Claim

against the Company, any Subsidiary or against any person or entity whose liability for any Environmental Claim the Company or any Subsidiary

has retained or assumed either contractually or by operation of law, except as would not, individually or in the aggregate, have a Material

Adverse Effect (for the avoidance of doubt, the operation of vessels in the ordinary course of business shall not be deemed, by itself,

an action, activity, circumstance or condition set forth in this clause (c)); and (d) none of the Company or any Subsidiary is subject

to any pending proceeding under Environmental Law to which a Governmental Authority is a party and which the Company reasonably believes

is likely to result in monetary sanctions of US$100,000 or more. Any existing compliance and remediation costs and liabilities arising

under Environmental Laws and resulting from the business, operations or properties of the Company or any Subsidiary would not, individually

or in the aggregate, reasonably be expected to have a Material Adverse Effect, except as set forth in or contemplated in the Registration

Statement and the Prospectus. No facts or circumstances have come to the Company’s attention that could result in costs or liabilities

that could be expected, individually or in the aggregate, to have a Material Adverse Effect.

(xxxiii) The Company

and each of the Subsidiaries (A) is in compliance, in all material respects, with applicable foreign, federal, state and local laws,

rules, regulations, statutes and codes promulgated by applicable governmental authorities (including pursuant to the Occupational Health

and Safety Act) relating to the protection of human health and safety in the workplace (“Occupational Laws”);

(B) has received all material permits, licenses or other approvals required of it under applicable Occupational Laws to conduct its

business as currently conducted; and (C) is in compliance, in all material respects, with all terms and conditions of such permit,

license or approval. No action, proceeding, revocation proceeding, writ, injunction or claim is pending or, to the Company’s knowledge,

threatened against the Company or any of its Subsidiaries relating to Occupational Laws, and the Company does not have knowledge of any

facts, circumstances or developments relating to its operations or cost accounting practices that could reasonably be expected to form

the basis for or give rise to such actions, suits, investigations or proceedings that could be expected, individually or in the aggregate,

to have a Material Adverse Effect.

(xxxiv) No material labor

problem or dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is threatened

or imminent.

(xxxv) The Company has

not, and no one acting on its behalf has, (a) taken, directly or indirectly, any action designed to cause or to result in the stabilization

or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (b) sold, bid

for, purchased, or paid any compensation for soliciting purchases of, any of the Shares or (c) paid or agreed to pay to any person

any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (b) and

(c), compensation paid to the Agent in connection with the sale of the Shares.

(xxxvi) Other than the

Agent or any of its designees, no person or entity has the right to act as a placement agent, underwriter or as a financial advisor in

connection with the sale of the Shares contemplated hereby, and the Company is not a party to any agreement with an agent or underwriter

for any other “at the market” offering or continuous equity transaction.

10

(xxxvii) There is no

transaction, arrangement or other relationship between the Company or any of its Subsidiaries and an unconsolidated or other off balance

sheet entity that is required to be disclosed by the Company in the Registration Statement or the Prospectus and is not so disclosed or

that otherwise could be reasonably likely to have a Material Adverse Effect.

(xxxviii) To the Company’s

knowledge, none of the Company, its Subsidiaries, or any of their respective affiliates, nor any person or entity acting on their behalf

(excluding the Agent and any of its other designees, as applicable) has, directly or indirectly, made any offers or sales of any security

or solicited any offers to buy any security, under circumstances that would cause the transactions contemplated by this Agreement to require

approval of stockholders of the Company under any applicable stockholder approval provisions, including, without limitation, under the

rules and regulations of Nasdaq. None of the Company, its Subsidiaries, their affiliates nor any person or entity acting on their

behalf will take any action or steps that would cause the offering of any of the Shares to be integrated with other offerings of securities

of the Company.

(xxxix) Any statistical

and market-related data included in the Registration Statement and the Prospectus are based on or derived from sources that the Company

believes to be reliable and accurate and, to the extent required, the Company has obtained the written consent to the use of such data

from such sources.

(xxx) The Registration

Statement is not the subject of a pending proceeding or examination under Section 8(d) or 8(e) of the Securities Act, and

the Company is not the subject of a pending proceeding under Section 8A of the Securities Act in connection with the offering of

the Shares.

(xxxi) The Company and

its board of directors has taken all necessary action, if any, in order to render inapplicable any control share acquisition, business

combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s

articles of incorporation, or the laws of the State of Nevada that is or could become applicable to the purchasers of the Shares.

(xxxii) The Company and

its ERISA Affiliates (as defined hereafter) maintain one or more “employee benefit plans,” as defined in Section 3(3) of

the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The plan(s) is/are referred

to collectively herein as the “Employee Plans.” An “ERISA Affiliate” of any person

or entity means any other person or entity that, together with that person or entity, could be treated as a single employer under Section 414(b),

(c), (m) or (o) of the Internal Revenue Code of 1986, as amended (the “Code”). Each Employee Plan

has been maintained in material compliance with its terms and the requirements of applicable law. No Employee Plan is subject to Title

IV of ERISA. The Registration Statement, Preliminary Prospectus and the Prospectus identify each material employment, severance or other

similar agreement, arrangement or policy that is required to be disclosed pursuant to the Rules and Regulations providing for insurance

coverage (including any self-insured arrangements), workers’ compensation, disability benefits, severance benefits, supplemental

unemployment benefits, vacation benefits or retirement benefits, or deferred compensation, profit-sharing, bonuses, stock options, stock

appreciation rights or other forms of incentive compensation, or post-retirement insurance, compensation or benefits that : (i) is

not an Employee Plan; (ii) is entered into, maintained or contributed to, as the case may be, by the Company or any of its ERISA

Affiliates; and (iii) covers any officer or director or former officer or director of the Company or any of its ERISA Affiliates.

These agreements, arrangements, policies or plans are referred to collectively as “Benefit Arrangements”. Each

Benefit Arrangement has been maintained in material compliance with its terms and with the requirements of applicable law. Except as disclosed

in the Registration Statement, Preliminary Prospectus and the Prospectus, there is no liability in respect of post-retirement health and

medical benefits for retired employees of the Company or any of its ERISA Affiliates, other than medical benefits required to be continued

under applicable law. No non-exempt “prohibited transaction” (as defined in either Section 406 of ERISA or Section 4975

of the Code) has occurred with respect to any Employee Plan and each Employee Plan that is intended to be qualified under Section 401(a) of

the Code is so qualified, and nothing has occurred, whether by action or by failure to act, that could cause the loss of such qualification.

(xxxiii) Neither the

Company nor any Subsidiary or any of their respective properties or assets has any immunity from the jurisdiction of any court or from

any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise) under

the laws of the United States or any political subdivisions thereof.

11

(xxxiv) The Company is

not a “foreign private issuer” as defined in Rule 405 promulgated under the Securities Act.

(xxxv) The Company did

not qualify as a “passive foreign investment company” within the meaning of Section 1297 of the United States Internal

Revenue Code of 1986, as amended, for its most recently completed taxable year, if any.

(xxxvi) Each “forward-looking

statement” (within the meaning of Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the

Registration Statement and the Prospectus has been made or reaffirmed with a reasonable basis and has been disclosed in good faith.

(xxxvii) The interactive

data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the

information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines

applicable thereto.

(xxxviii) At the time

the Registration Statement was or will be filed with the Commission, at the time the Registration Statement was or will be declared effective

by the Commission, and at the time the Company’s most recent Annual Report on Form 10-K was filed with the Commission, the

Company met or will meet the then-applicable requirements for the use of Form S-3 under the Securities Act, including, but not limited

to, General Instruction I.B.6. of Form S-3, if and for so long as applicable.

(xxxix) (i) Except

as may be included or incorporated by reference in the Registration Statement and the Prospectus, (a) there has been no material

security breach or other material compromise of or relating to any of the Company’s information technology and computer systems,

networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party

data maintained by or on behalf of them), equipment or technology (collectively, “IT Systems and Data”) that

resulted in a legal or contractual obligation of the Company to notify any other person about such occurrence; and (b) the Company

has not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any material

security breach or other material compromise to its IT Systems and Data; (ii) the Company is presently in compliance with all material

applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory

authority, and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems

and Data from unauthorized use, access, misappropriation or modification, except as would not, in the case of this clause (ii), individually

or in the aggregate, result in a Material Adverse Effect; (iii) the Company has implemented backup and disaster recovery technology

consistent with industry standards and practices; and (iv) the IT Systems and Data are adequate for, and operate and perform in all

material respects as required in connection with, the operation of the business of the Company as currently conducted, except where such

failure would not reasonably be expected to result in a Material Adverse Effect, and the Company has implemented and maintained commercially

reasonable controls, policies, procedures and safeguards to maintain and protect its material confidential information and the integrity,

continuous operation, redundancy and security of the IT Systems and Data.

(xl) The Company has

not received from the Commission any notice pursuant to Rule 401(g)(1) under the Securities Act objecting to the use of the

Registration Statement, and the Company has complied to the Commission’s satisfaction with all requests of the Commission for additional

or supplemental information related to the Registration Statement and the Prospectus. In the section entitled “Plan of Distribution”

in the Prospectus Supplement, the Company has named A.G.P./Alliance Global Partners as an agent that the Company has engaged in connection

with the transactions contemplated by this Agreement.

(xli) Copies of the Registration

Statement, the Prospectus, and all amendments or supplements thereto and all Incorporated Documents that were filed with the Commission

on or prior to the date of this Agreement have been delivered, or are publicly available through EDGAR, to the Agent. Each Prospectus

delivered to the Agent for use in connection with the sale of the Shares pursuant to this Agreement will be identical to the version of

such Prospectus filed with the Commission via EDGAR, except to the extent permitted by Regulation S-T.

12

(xlii) There are no persons

with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or

included in the Offering, except for such rights as have been duly waived.

(xliii) Except as disclosed

in the Registration Statement and the Prospectus, subsequent to the respective dates as of which information is given in the Registration

Statement and the Prospectus, no executive officer or director of the Company has resigned from any position with the Company.

(xliv) LMHS, P.C. has not,

during the periods covered by the financial statements included or incorporated by reference in the Registration Statement and the Prospectus,

provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.

(xlv) The holders of the outstanding

shares of Common Stock have no rights of rescission with respect thereto. The offers and sales of the outstanding shares of Common Stock

were at all relevant times either registered under the Securities Act and the applicable state securities or “blue sky” laws

or, based in part on the representations and warranties of the purchasers of such shares, exempt from such registration requirements.

The description of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights

granted thereunder, as described in the Registration Statement and the Prospectus, accurately and fairly present, in all material respects,

the information required to be shown with respect to such plans, arrangements, options and rights.

(xlvi) The Company is not

aware that any key employee or significant group of employees of the Company or any Subsidiary plans to terminate employment with the

Company or any such Subsidiary.

(xlvii) The Company has not

relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice in connection with the offering and sale

of the Shares.

(xlviii) Neither the Company

nor any of its related entities (i) is required to register as a “broker” or “dealer” in accordance with

the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls or is a “person

associated with a member” or “associated person of a member” (within the meaning of Article I of the NASD Manual

administered by FINRA). To the Company’s knowledge, there are no affiliations or associations between any member of FINRA and any

of the Company’s officers, directors or 10% or greater security holders, except as set forth in the Registration Statement.

(xlix) The Company is not

a shell company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar months

previously and if it has been a shell company at any time previously, has filed current Form 10 information (as defined in General

Instruction I.B.6 of Form S-3) with the Commission at least 12 calendar months previously reflecting its status as an entity that

is not a shell company.

(l) All of the information

provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers and directors and, to the Company’s

knowledge, the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the Offering

is true, complete, correct and compliant with FINRA’s rules in all material respects and any letters, filings or other supplemental

information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct in all material respects.

Except as disclosed in the Registration Statement and the Prospectus, there is no (i) officer or director of the Company, (ii) beneficial

owner of 10% or more of any class of the Company’s securities or (iii) to the Company’s knowledge, beneficial owner of

the Company’s unregistered equity securities that were acquired during the 180-day period immediately preceding the date of this

Agreement that is an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with

the rules and regulations of FINRA).

(li) Each agreement or other

instrument to which the Company or any of its Subsidiaries is a party or by which it is or may be bound and (i) that is referred

to in the Registration Statement and the Prospectus, or (ii) is material to the Company’s or its Subsidiaries’ business,

has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable

against the Company or any of its Subsidiaries and, to the Company’s knowledge, the other parties thereto, in accordance with its

terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’

rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and state

securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject

to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. Except as disclosed

in the Registration Statement and the Prospectus, none of such agreements or instruments has been assigned by the Company or its Subsidiaries.

13

(lii) No payments or inducements

have been made or given, directly or indirectly, to any federal or local official or candidate for any federal or state office in the

United States or foreign offices by the Company, any of its Subsidiaries or any of their officers or directors, or, to the knowledge of

the Company, by any of its employees or agents or any other person in connection with any opportunity, contract, permit, certificate,

consent, order, approval, waiver or other authorization relating to the business of the Company or any of its Subsidiaries, except for

such payments or inducements as were lawful under applicable laws, rules and regulations. Neither the Company, any of its Subsidiaries,

nor, to the knowledge of the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the

Company or any of its Subsidiaries, (i) has used any corporate funds for any unlawful contribution, gift, entertainment or other

unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any government official or

employee from corporate funds; or (iii) made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment

in connection with the business of the Company.

(liii) The Company owns no

“margin securities” as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal

Reserve Board”), and none of the proceeds from the issuance, sale and delivery of the Shares as contemplated by this Agreement

will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring

any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any

of the shares of Common Stock to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal

Reserve Board.

(liv) The qualifications of

the persons serving as board members of the Company and the overall composition of the Company’s board of directors comply with

the applicable requirements of the Exchange Act and the Sarbanes-Oxley Act and the listing rules of Nasdaq applicable to the Company.

At least one member of the Audit Committee of the board of directors of the Company qualifies as an “audit committee financial expert,”

as such term is defined under Regulation S-K and the listing rules of Nasdaq. In addition, at least a majority of the persons serving

on the board of directors of the Company qualify as “independent,” as defined under the listing rules of Nasdaq.

(lv) The Company has not filed

a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing of its last Annual Report on Form 10-K,

indicating that it (i) has failed to pay any dividend or sinking fund installment on preferred stock or (ii) has defaulted on

any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in

the aggregate, could reasonably be expected to result in a Material Adverse Effect.

(lvi) The minute books of

the Company and each of its Subsidiaries have been made available to the Agent and counsel for the Agent, and such books (i) contain

a substantially complete summary of all meetings and material actions of the board of directors (including each board committee) and stockholders

of the Company (or analogous governing bodies and interest holders, as applicable) during the past twelve (12) months, and (ii) accurately

reflect in all material respects all transactions referred to in such minutes.

(lvii) The disclosures in

the Registration Statement and the Prospectus concerning the effects of federal, state, local and all foreign regulation on the Company’s

business in the past and as currently contemplated are correct in all material respects and no other such regulations are required to

be disclosed in the Registration Statement and the Prospectus which are not so disclosed.

(lviii) To the Company’s

knowledge, no director, officer, key employee or consultant of the Company is subject to any confidentiality, non-disclosure, non-competition

agreement or non-solicitation agreement with any employer or prior employer that could reasonably be expected to materially affect his

or her ability to be and act in his or her respective capacity with the Company or be expected to result in a Material Adverse Effect.

14

(lix) To the Company’s

knowledge, all material technical information developed by and belonging to the Company or any of its Subsidiaries which has not been

patented has been kept confidential. Neither the Company nor any of its Subsidiaries is a party to or bound by any options, licenses or

agreements with respect to the Intellectual Property of any other person or entity that are required to be set forth in the Registration

Statement and the Prospectus and are not described therein. None of the technology employed by the Company or its Subsidiaries has been

obtained or is being used by the Company or any of its Subsidiaries in violation of any contractual obligation binding on the Company

or any such Subsidiary or, to the Company’s knowledge, any of its or its Subsidiaries’ officers, directors or employees, or

otherwise in violation of the rights of any persons, except for violations that would not result in a Material Adverse Effect.

(b) Any certificate signed

by any officer of the Company and delivered to the Agent or the Agent’s counsel shall be deemed a representation and warranty by

the Company to the Agent as to the matters covered thereby.

2. Purchase, Sale and

Delivery of Shares.

(a) At the Market

Sales. On the basis of the representations, warranties and agreements herein the Company agrees that, from time to time during the

term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent or any of

its designees, acting as sales agent, the Shares up to an aggregate offering price of US$7,200,000; provided, however, that in no event

shall the Company issue or sell through the Agent or any of its designees such number of Shares that (a) exceeds the number or dollar

amount of Common Stock registered on the Registration Statement, pursuant to which the Offering is being made, (b) exceeds the number

of authorized but unissued Common Stock under the Company’s articles of incorporation, (c) would cause the Company or the offering

of the Shares to not satisfy the eligibility and transaction requirements for use of Form S-3 (including General Instruction I.B.1

of Form S-3), (d) exceeds the amount authorized from time to time to be issued and sold under this Agreement by the Company’s

board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing,

or (e) exceeds the number or dollar amount of Shares of Common Stock for which the Company has filed the Prospectus or other prospectus

supplement specifically relating to the offering of the Shares pursuant to this Agreement (the lesser of (a), (b), (c), (d) and (e),

the “Maximum Amount”)). Notwithstanding anything to the contrary contained herein, the parties hereto agree

that compliance with the limitations set forth in this Section 2(a) on the number and aggregate sales price of Shares

issued and sold under this Agreement shall be the sole responsibility of the Company and that neither the Agent nor any of its designees

shall have any obligation in connection with such compliance. As used herein, the term “business day” means

any day (other than Saturday, Sunday or any federal holiday in the United States) in which commercial banks in New York, New York are

open for business.

(i) For purposes of selling

the Shares through the Agent and any designee, the Company hereby appoints the Agent as exclusive agent of the Company for the purpose

of soliciting purchases of the Shares from the Company pursuant to this Agreement and the Agent agrees to use its commercially reasonable

efforts to sell the Shares on the terms and subject to the conditions stated herein.

(ii) Each time the Company

wishes to issue and sell the Shares hereunder (each, a “Transaction”), it will notify the Agent by telephone

(confirmed promptly by facsimile or e-mail to the appropriate individual listed on Schedule D hereto, using a form substantially

similar to that set forth on Schedule C hereto (a “Transaction Notice”)) as to the maximum number of

Shares to be sold by the Agent or any of its designees on such day and in any event not in excess of the amount available for issuance

under the Prospectus and the currently effective Registration Statement, the time period during which sales are requested to be made,

any limitation on the number of shares that may be sold in any one Trading Day (as defined below), and any minimum price below which sales

may not be made. The Transaction Notice shall originate from any of the individuals from the Company set forth on Schedule B (with

a copy to each of the other individuals from the Company listed on such Schedule) and shall be addressed to each of the individuals from

the Agent or any of its designees, as applicable, set forth on Schedule D, as such Schedule B and Schedule D may

be amended from time to time. The Transaction Notice shall be effective upon receipt by the Agent unless and until (i) the Agent

declines to accept for any reason, in its sole discretion, (ii) the entire amount of the Shares have been sold, (iii) the Company

suspends or terminates the Transaction Notice in accordance with the notice requirements set forth in this Section 2, (iv) the

Company issues a subsequent Transaction Notice with parameters superseding those on the earlier dated Transaction Notice, or (v) this

Agreement has been terminated under the provisions of Section 7. Subject to the terms and conditions hereof and unless the

sale of the Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement,

the Agent shall use its commercially reasonable efforts to sell all of the Shares so designated by the Company in, and in accordance with

the terms set forth in, the Transaction Notice; provided, however, that any obligation of the Agent to use such commercially reasonable

efforts shall be subject to the continuing accuracy of the representations and warranties of the Company herein, to the performance by

the Company of its obligations hereunder and to the continuing satisfaction of the additional conditions specified in Section 4

of this Agreement. The gross sales price of the Shares sold under this Section 2(a) shall be equal to the market price

for the Common Stock sold by the Agent or any of its designees under this Section 2(a) on Nasdaq at the time of such

sale. For the purposes hereof, “Trading Day” means any day on which Common Stock are purchased and sold on the

principal market on which the Common Stock are listed or quoted.

15

(iii) The Company or

the Agent may, upon notice to the other party hereto by telephone (confirmed promptly by facsimile or e-mail to the respective individuals

of the other party set forth on Schedule D hereto, which confirmation shall be promptly acknowledged by the other party), suspend

the Offering for any reason and at any time, whereupon the Agent shall so suspend the offering of Shares until further notice is provided

by the other party to the contrary; provided, however, that such suspension or termination shall not affect or impair the

parties’ respective obligations with respect to the Shares sold hereunder prior to the receipt by the Agent of such notice. Each

of the parties agrees that no such notice under this Section 2(a)(iii) shall be effective against the other unless it

is made to one of the individuals named on Schedule D hereto, as such Schedule may be amended from time to time.

(iv) The

Company acknowledges and agrees that (A) there can be no assurance that the Agent or any of its designees will be successful in selling

the Shares, (B) neither the Agent nor any of its designees will incur any liability or obligation to the Company or any other person

or entity if Shares are not sold for any reason other than a failure by the Agent or any of its designees to use commercially reasonable

efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such Shares as required under

this Agreement, and (C) neither the Agent nor any of its designees shall be under any obligation to purchase Shares on a principal

basis pursuant to this Agreement, except as otherwise agreed by the Agent and the Company in writing and expressly set forth in a Transaction

Notice.

(v) Subject to the terms

of the applicable Transaction Notice, the Agent or any of its designees may sell Shares by any method permitted by law to be an “at

the market offering” as defined in Rule 415 under the Securities Act, including, without limitation, sales made directly on

Nasdaq, on any other existing trading market for the Common Stock or to or through a market maker, and including sales made during pre-market

or post-market trading sessions to the extent authorized by the Company in the applicable Transaction Notice. Subject to the terms of

the applicable Transaction Notice, the Agent or any of its designees may also sell Shares by any other method permitted by law, including

but not limited to in negotiated transactions, with the Company’s prior written consent. In addition, the Company and the Agent

may from time to time agree in writing, as expressly set forth in a Transaction Notice, that the Agent will purchase Shares from the Company

as principal in separately negotiated transactions, including block trades, at a price and on such other terms as are agreed upon by the

Company and the Agent at the time of such transaction; provided that any such principal transaction shall be subject to the Maximum Amount

and the other limitations set forth in this Section 2(a).

(vi) The compensation

to the Agent for sales of the Shares, as an agent of the Company, shall be a cash transaction fee equal to three percent (3.0%) (the “Transaction

Fee”) of the gross sales price of all of Shares sold pursuant to this Section 2(a). The remaining proceeds,

after further deduction for any transaction fees, trading expenses or execution fees imposed by any clearing organization or any governmental

or self-regulatory organization and any other fees or expenses incurred by the Agent in respect of such sales, including, but not limited

to, up to $0.002 per Share sold pursuant to this Agreement, shall constitute the net proceeds to the Company for such Shares (the “Net

Proceeds”). The Agent shall notify the Company as promptly as practicable if any deduction referenced in the preceding sentence

will be required.

(vii) The Agent shall

provide written confirmation (which may be by facsimile or electronic mail) to the Company following the close of trading on Nasdaq each

day in which the Shares are sold under this Section 2(a) setting forth the number of the Shares sold on such day by the

Agent or any of its designees, the aggregate gross sale proceeds, the Net Proceeds to the Company, and the compensation payable by the

Company to the Agent with respect to such sales.

16

(viii) All Shares sold

pursuant to this Section 2(a) will be delivered by the Company to the Agent or any of its designees for the accounts

of the Agent or such designee on the first (1st) full business day following the date on which such Shares are sold, or at

such other time and date as Agent and the Company determine pursuant to Rule 15c6-1(a) under the Exchange Act, each such time

and date of delivery being herein referred to as a “Settlement Date.” On each Settlement Date, the Shares sold

through the Agent or any of its designees for settlement on such date shall be issued and delivered by the Company to the Agent or such

designee against payment of the Net Proceeds from the sale of such Shares. Settlement for all such Shares shall be effected by free delivery

of the Shares by the Company or its transfer agent (i) to the Agent or such designee’s account (provided the Agent shall have

given the Company written notice of such designee prior to the Settlement Date) at The Depository Trust Company (“DTC”)

or (ii) by such other means of delivery as may be mutually agreed upon by the parties hereto, which in all cases (provided that such

Shares were sold pursuant to the Registration Statement) shall be freely tradable, transferable, registered shares in good deliverable

form, in return for payment in same day funds delivered to an account designated by the Company. If the Company or its transfer agent

(if applicable) shall default on its obligation to deliver the Shares on any Settlement Date, the Company shall (A) indemnify and

hold the Agent and its designees harmless against any loss, claim or damage arising from or as a result of such default by the Company

and (B) pay the Agent any commission to which it would otherwise be entitled absent such default against payment of the Net Proceeds

therefor by wire transfer of same day funds payable to the order of the Company at 9:00 a.m. New York City time.

(ix) Under no circumstances

shall the Company cause or request the offer or sale of any Shares if, after giving effect to the sale of such Shares, the aggregate gross

sales proceeds sold pursuant to this Agreement would exceed the lesser of (A) together with all sales of Shares under this Agreement,

the Maximum Amount, (B) the amount available for offer and sale under the currently effective Registration Statement and (C) the

amount authorized from time to time to be issued and sold under this Agreement by the Company’s board of directors, a duly authorized

committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Under no circumstances shall the Company

cause or request the offer or sale of any Shares at a price lower than the minimum price authorized from time to time by the Company’s

board of directors, duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing.

Further, under no circumstances shall the aggregate offering amount of the Shares sold pursuant to this Agreement, including any separate

underwriting or similar agreement covering principal transactions, exceed the Maximum Amount.

(x) Unless the exceptive

provisions set forth in Rule 101(c)(1) of Regulation M under the Exchange Act are satisfied with respect to the Shares, the

Company shall give the Agent at least one business day’s prior notice of its intent to sell any Shares in order to allow the Agent

and any of its designees time to comply with Regulation M.

(xi) The Company agrees

that during the term of this Agreement, any offer to sell, any solicitation of an offer to buy, or any sales of Shares in an “at

the market offering” as defined in Rule 415 under the Securities Act, including pursuant to Section 3(o) of

this Agreement, shall only be effected by or through the Agent or any of its designees; provided, however, that the foregoing limitation

shall not apply to the exercise of any outstanding stock option or warrant described in the Registration Statement and the Prospectus.

(b) Nothing herein contained

shall constitute the Agent or any of its designees as an unincorporated association or partner with the Company. Under no circumstances

shall any Shares be sold pursuant to this Agreement after the date which is three years after the Registration Statement is first declared

effective by the Commission.

(c) Notwithstanding any

other provisions of this Agreement, the Company agrees that no sale of Shares shall take place, and the Company shall not request the

sale of any Shares, and neither the Agent nor or any of its designees shall be obligated to sell, during any period in which the Company

is, or could be deemed to be, in possession of material non-public information.

17

3. Covenants.

The Company covenants and agrees with the Agent as follows:

(a) After the date hereof

and through any Prospectus Delivery Period, prior to amending or supplementing the Registration Statement (including any Rule 462(b) Registration

Statement), Base Prospectus, Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus related to this Agreement,

the Company shall furnish to the Agent for review a copy of each such proposed amendment or supplement, allow the Agent a reasonable amount

of time to review and comment on such proposed amendment or supplement, and the Company shall not file any such proposed amendment or

supplement to which the Agent or counsel to the Agent reasonably object; provided, that the foregoing shall not apply with regards to

the filing by the Company of any Form 10-K, Form 10-Q, Form 8-K or other Incorporated Document. Subject to this Section 3(a),

immediately following execution of this Agreement, the Company will prepare a prospectus supplement describing the selling terms of the

Shares hereunder, the plan of distribution thereof and such other information as may be required by the Securities Act or the Rules and

Regulations or as the Agent and the Company may deem appropriate, and if requested by the Agent, a Permitted Free Writing Prospectus containing

the selling terms of the Shares hereunder and such other information as the Company and the Agent may deem appropriate, and will file

or transmit for filing with the Commission, in accordance with Rule 424(b) or Rule 433, as the case may be, copies of the

Prospectus as supplemented and each such Permitted Free Writing Prospectus.

(b) After the date of

this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests for additional

or supplemental information from, the Commission or for any amendments or supplements to the Registration Statement, the Base Prospectus,

Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus (excluding any Incorporated Documents), (ii) of the

time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any Base Prospectus,

Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus (excluding any Incorporated Documents), (iii) of the

time and date that any post-effective amendment to the Registration Statement becomes effective, (iv) of the issuance by the Commission

of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or of any order preventing

or suspending its use or the use of any Base Prospectus, Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus,

or (v) of any proceedings to remove, suspend or terminate from listing or quotation the Common Stock from any securities exchange

upon which it is listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for

any of such purposes. If the Commission shall enter any such stop order at any time, the Company or the Agent may elect to terminate this

Agreement. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430B and 430C, as applicable,

under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b), Rule 433

or Rule 462 were received in a timely manner by the Commission (without reliance on Rule 424(b)(8) or Rule 164(b)).

(c) (i) From the

date hereof through the later of (A) the termination of this Agreement and (B) the end of any applicable Prospectus Delivery

Period, the Company will comply with all requirements imposed upon it by the Securities Act, as now and hereafter amended, and by the

Rules and Regulations, as from time to time in force, and by the Exchange Act so far as necessary to permit the continuance of sales

of or dealings in the Shares as contemplated by the provisions hereof, the Base Prospectus, Prospectus Supplement, the Prospectus and

any Permitted Free Writing Prospectus. If during any applicable Prospectus Delivery Period any event occurs as a result of which the Base

Prospectus, Prospectus Supplement, the Prospectus, or any Permitted Free Writing Prospectus would include an untrue statement of a material

fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading,

or if during any applicable Prospectus Delivery Period it is necessary or appropriate in the opinion of the Company or its counsel, or

in the reasonable opinion of the Agent or counsel to the Agent to amend the Registration Statement or supplement the Base Prospectus,

Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus, to comply with the Securities Act or to file under the

Exchange Act any document which would be deemed to be incorporated by reference in the Prospectus in order to comply with the Securities

Act or the Exchange Act, the Company will promptly notify Agent , and the Agent shall suspend the offering and sale of any such Shares,

and the Company will amend the Registration Statement or supplement the Base Prospectus, Prospectus Supplement, the Prospectus or any

Permitted Free Writing Prospectus or file such document (at the expense of the Company) so as to correct such statement or omission or

effect such compliance within the time period prescribed by the Securities Act or the Exchange Act.

(ii) In case the Agent

is required to deliver (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), in

connection with the sale of the Shares, a Prospectus after the nine-month period referred to in Section 10(a)(3) of the Securities

Act, or after the time a post-effective amendment to the Registration Statement is required pursuant to Item 512(a) of Regulation

S-K under the Securities Act, the Company will prepare, at its expense, promptly upon request such amendment or amendments to the Registration

Statement and the Prospectus as may be necessary to permit compliance with the requirements of Section 10(a)(3) of the Securities

Act or Item 512(a) of Regulation S-K under the Securities Act, as the case may be. The Company shall cause each amendment or supplement

to any Base Prospectus or the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of

the Securities Act or, in the case of any document which would be deemed to be incorporated by reference therein, to be filed with the

Commission as required pursuant to the Exchange Act, within the time period prescribed. The Company shall promptly notify the Agent if

any Material Contract is terminated or if the other party thereto gives written notice of its intent to terminate any such Material Contract.

18

(iii) If at any time

following issuance of a Permitted Free Writing Prospectus there occurs an event or development as a result of which such Permitted Free

Writing Prospectus would conflict with the information contained in the Registration Statement, the Base Prospectus, Prospectus Supplement

or the Prospectus, or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary

in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company

promptly will notify the Agent and will promptly amend or supplement, at its own expense, such Permitted Free Writing Prospectus to eliminate

or correct such conflict, untrue statement or omission.

(d) The Company shall

use commercially reasonable efforts to take or cause to be taken all necessary action to qualify the Shares for sale under the securities

laws of such jurisdictions as Agent reasonably designates, if applicable, and to continue such qualifications in effect so long as required

for the distribution of the Shares, except that the Company shall not be required in connection therewith to qualify as a foreign corporation

or to execute a general consent to service of process in any state. The Company shall promptly advise the Agent of the receipt by the

Company of any notification with respect to the suspension of the qualification of the Shares for offer or sale in any jurisdiction or

the initiation or threatening of any proceeding for such purpose.

(e) The Company will

furnish to the Agent and counsel for the Agent, to the extent requested, copies of the Registration Statement, the Base Prospectus, Prospectus

Supplement, the Prospectus, any Permitted Free Writing Prospectus, and all amendments and supplements to such documents, in each case

as soon as available and in such quantities as the Agent may from time to time reasonably request and, at the Agent’s request, will

also furnish copies of the Prospectus to each exchange or market on which sales of the Shares may be made.

(f) The Company will

make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the

Company’s current fiscal quarter, an earnings statement (which need not be audited) covering a 12-month period that shall satisfy

the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations. If the Company makes

any public announcement or release disclosing its results of operations or financial condition for a completed quarterly or annual fiscal

period (each, an “Earnings Release”) and the Company has not yet filed an Annual Report on Form 10-K or

a Quarterly Report on Form 10-Q with respect to such information, as applicable, then, prior to any sale of Shares, the Company shall

be obligated to (x) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b), which prospectus

supplement shall include the applicable financial information or (y) file a Current Report on Form 8-K, which Current Report

on Form 8-K shall include the applicable financial information.

(g) The Company, whether

or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to be paid (i) all

expenses (including stock or transfer taxes and stamp or similar duties allocated to the respective transferees) incurred in connection

with the registration, issue, sale and delivery of the Shares, (ii) all reasonable expenses and fees (including, without limitation,

fees and expenses of the Company’s accountants and counsel) in connection with the preparation, printing, filing, delivery, and

shipping of the Registration Statement (including the financial statements therein and all amendments, schedules, and exhibits thereto),

the Base Prospectus, each Prospectus Supplement, Prospectus, any Permitted Free Writing Prospectus, and any amendment thereof or supplement

thereto, and the producing, word-processing, printing, delivery, and shipping of this Agreement and other closing documents, including

Blue Sky Memoranda (covering the states and other applicable jurisdictions) prepared by counsel, if required, and including the cost to

furnish copies of each thereof to the Agent, (iii) all filing fees, (iv) listing fees, if any, (v) the cost and expenses

of the Company relating to investor presentations or any “roadshow” undertaken in connection with marketing of the Shares

as agreed to by the Company, and (vi) all other costs and expenses of the Company incident to the performance of its obligations

hereunder that are not otherwise specifically provided for herein. The Company shall reimburse the Agent upon request for its reasonable

costs and out-of-pocket expenses incurred in connection with this Agreement, including settlement and DTC fees, and the fees and out-of-pocket

expenses of its legal counsel, in an amount not to exceed (except in the case of legal fees and disbursements as provided for below) US$35,000

in connection with the filing of the initial Prospectus Supplement for the Offering of the Shares. In addition, the Company shall reimburse

the Agent upon request for its reasonable costs, fees and expenses incurred in connection with this Agreement, inclusive of legal fees,

in an amount not to exceed US$2,500 on each Bringdown Date. In addition, the Company shall reimburse the Agent for its expenses (including

but not limited to the reasonable fees and documented out-of-pocket costs and expenses of counsel to the Agent) up to US$5,000 for each

program “refresh” (filing of a new registration statement, prospectus, or prospectus supplement relating to the Shares and/or

an amendment of this Agreement) executed pursuant to this Agreement. The Company shall also reimburse the Sales Agent for background reports

on certain employees and affiliates of the Company in an amount not to exceed $3,000. All such reimbursements under this Agreement shall

be paid in U.S. dollars.

19

(h) The Company will

apply the net proceeds from the sale of the Shares in the manner set forth under the caption “Use of Proceeds” in the Base

Prospectus, Prospectus Supplement, the Prospectus, and any Permitted Free Writing Prospectus.

(i) The Company will

not, without (i) giving the Agent at least five business days’ prior written notice specifying the nature of the proposed sale

and the date of such proposed sale and (ii) the Agent’s suspending activity under this Agreement for such period of time as

requested by the Company or as deemed appropriate by the Agent in light of the proposed sale, offer for sale, sell, contract to sell,

pledge, grant any option for the sale of, enter into any transaction which is designed to, or might reasonably be expected to, result

in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Company

or any Subsidiary, or otherwise issue or dispose of, directly or indirectly (or publicly disclose the intention to make any such offer,

sale, pledge, grant, issuance or other disposition), of any Common Stock or any securities convertible into or exchangeable for, or any

options or rights to purchase or acquire, Common Stock, or permit the registration under the Securities Act of any Common Stock, such

securities, options or rights, except for (i) the registration of the Shares and the sales through the Agent or any of its designees

pursuant to this Agreement, (ii) the registration of Common Stock issued or issuable with respect to any currently outstanding stock

options and warrants that are described in the Registration Statement and the Prospectus and (iii) a registration statement on Form S-8

relating to employee benefit plans, or any reoffer prospectus filings made with the Commission in connection therewith.

(j) The Company shall

not, at any time at or after the execution of this Agreement, offer or sell any Shares by means of any “prospectus” (within

the meaning of the Securities Act), or use any “prospectus” (within the meaning of the Securities Act) in connection with

the offer or sale of the Shares, in each case other than the Prospectus or any Permitted Free Writing Prospectus.

(k) Until the termination

of this Agreement, the Company will not take, directly or indirectly, any action designed to or that would constitute or that might reasonably

be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation in violation of the Securities Act,

the Exchange Act or the rules and regulations thereunder of the price of any security of the Company to facilitate the sale or resale

of the Shares or otherwise violate any provision of Regulation M under the Exchange Act.

(l) The Company will

not incur any liability for any finder’s or broker’s fee or agent’s commission in connection with the execution and

delivery of this Agreement or the consummation of the transactions contemplated hereby or thereby, except as contemplated herein.

(m) During any applicable

Prospectus Delivery Period, the Company will file on a timely basis with the Commission such periodic and current reports as required

by the Rules and Regulations.

(n) The Company has maintained

and will maintain, such controls and other procedures, including without limitation those required by Sections 302 and 906 of the Sarbanes-Oxley

Act and the applicable regulations thereunder, that are designed to ensure that information required to be disclosed by the Company in

the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified

in the Commission’s rules and forms, including without limitation, controls and procedures designed to ensure that information

required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated

to the Company’s management, including its principal executive officer and its principal financial officer, or persons performing

similar functions, as appropriate to allow timely decisions regarding required disclosure, to ensure that material information relating

to Company is made known to them by others within those entities.

20

(o) Each of the Company

and Agent represent and agree that, neither the Company nor the Agent or any of its designees has made or will make any offer relating

to the Shares that would constitute an “issuer free writing prospectus,” as defined in Rule 433 under the Securities

Act, or that would otherwise constitute a “free writing prospectus,” as defined in Rule 405 under the Securities Act,

required to be filed with the Commission other than a Permitted Free Writing Prospectus. The Company represents that it has treated or

agrees that it will treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433,

and has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including

timely Commission filing where required, legending and record keeping.

(p) On the date hereof

and each date when the Company (A) amends or supplements (other than a supplement to a Prospectus filed pursuant to Rule 424(b) under

the Securities Act relating solely to the offering of securities other than the Shares) the Registration Statement or Prospectus by means

of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration

Statement or the Prospectus relating to the Shares, (B) files an Annual Report on Form 10-K under the Exchange Act (including

any Form 10-K/A containing amended material financial information or a material amendment to any previously filed Form 10-K)

or (C) files a Quarterly Report on Form 10-Q containing quarterly financial information that is incorporated by reference in

the Registration Statement and Prospectus (each of the dates in (A) through (C) are referred to herein as a “Bringdown

Date”), the Agent shall receive a favorable opinion of Stubbs Alderton & Markiles, LLP, counsel for the Company,

dated as of a date within ten (10) days after the applicable Bringdown Date, addressed to the Agent and modified as necessary to

relate to the Registration Statement and the Prospectus, as amended and supplemented to the time of delivery of such opinions. With respect

to this Section 3(p), in lieu of delivering such opinions or letters for Bringdown Dates subsequent to the date hereof, such

counsel may furnish agent with a letter (a “Reliance Letter”) to the effect that Agent may rely upon a prior

opinion or letter delivered under this Section 3(p) to the same extent as if it were dated the date of such letter (except

that statement in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus, as amended or supplemented

as of the date of such Reliance Letter); provided, however, the requirement to provide opinions and letters under this Section 3(p) is

hereby waived for any Bringdown Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until

the earlier to occur of the date the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding

the foregoing, if the Company subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and

did not provide Agent with opinions and letters under this Section 3(p), then before the Company delivers the Transaction

Notice or Agent sells any Shares, the Company shall cause Stubbs Alderton & Markiles, LLP to furnish to the Agent a written opinion

or Reliance Letter dated the date of the Transaction Notice.

(q) On the date hereof,

and each date when the Company files an Annual Report on Form 10-K, the Company shall cause LMHS, P.C. or other independent accountants

satisfactory to the Agent, to deliver to the Agent (A) a letter, dated as of a date within ten (10) days after such date and

addressed to Agent, in form and substance satisfactory to Agent (the first such letter, the “Initial Comfort Letter”),

confirming that they are independent public accountants within the meaning of the Securities Act and are in compliance with the applicable

requirements relating to the qualifications of accountants under Rule 2-01 of Regulation S-X of the Commission, and stating the conclusions

and findings of said firm with respect to the financial information and other matters and (B) a letter updating the Initial Comfort

Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and as modified

as necessary to relate to the date of such letter (each such letter, a “Bringdown Comfort Letter”); provided,

however, the requirement to provide a Bringdown Comfort Letter under this Section 3(q) is hereby waived for any Bringdown

Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to occur of the date

the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing, if the Company

subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide Agent with a

Bringdown Comfort Letter under this Section 3(q), then before the Company delivers the Transaction Notice or the Agent or

any of its designees sell any Shares, the Company shall cause LMHS, P.C., or other independent accountants satisfactory to the Agent,

to deliver to the Agent a Bringdown Comfort Letter dated the date of the Transaction Notice.

21

(r) On the date hereof

and each Bringdown Date, the Company shall furnish to the Agent a certificate, dated as of a date within ten (10) days after the

applicable Bringdown Date and addressed to the Agent, signed by the chief executive officer and by the chief financial officer of the

Company, to the effect that:

(i) The representations

and warranties of the Company in this Agreement are true and correct in all material respects as if made at and as of the date of the

certificate, and the Company has complied in all material respects with all the agreements and satisfied all the conditions on its part

to be performed or satisfied at or prior to the date of the certificate;

(ii) No stop order or

other order suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof or the qualification

of the Shares for offering or sale or notice that would prevent use of the Registration Statement, nor suspending or preventing the use

of the Base Prospectus, Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus, has been issued, and no proceeding

for that purpose has been instituted or, to the best of their knowledge, is contemplated by the Commission or any state or regulatory

body;

(iii) The Shares to be

sold on that date have been duly and validly authorized by the Company and all corporate action required to be taken for the authorization,

issuance and sale of the Shares on that date has been validly and sufficiently taken;

(iv) Subsequent to the

respective dates as of which information is given in the Base Prospectus, Prospectus Supplement, the Prospectus or any Permitted Free

Writing Prospectus, as amended and supplemented, and except for pending transactions disclosed therein, the Company has not incurred any

material liabilities or obligations, direct or contingent, or entered into any material transactions, not in the ordinary course of business,

or declared or paid any dividends or made any distribution of any kind with respect to its capital stock other than monthly cash dividends

on its Series A Convertible Preferred Stock, and there has not been any change in the capital stock or any issuance of options, restricted

stock units, warrants, convertible securities or other rights to purchase the capital stock (other than as a result of the exercise of

any currently outstanding options, restricted stock units or warrants that are disclosed in the Prospectus), or any material change in

the short-term or long-term debt, of the Company, or any Material Adverse Effect or any development that would reasonably be likely to

result in a Material Adverse Effect (whether or not arising in the ordinary course of business), or any material loss by strike, fire,

flood, earthquake, accident, epidemic, pandemic or other calamity, whether or not covered by insurance, incurred by the Company; and

(v) Except as stated

in the Base Prospectus, Prospectus Supplement, the Prospectus, and any Permitted Free Writing Prospectus, as amended and supplemented,

there is not pending, or, to the knowledge of the Company, threatened or contemplated, any action, suit or proceeding to which the Company

is a party before or by any court or governmental agency, authority or body, or any arbitrator, which would reasonably be likely to result

in any Material Adverse Effect; provided, however, the requirement to provide a certificate under this Section 3(r) is

hereby waived for any Bringdown Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until

the earlier to occur of the date the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding

the foregoing, if the Company subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and

did not provide the Agent with a certificate under this Section 3(r), then before the Company delivers the Transaction Notice

or the Agent or any of its designees sell any Shares, the Company shall provide the Agent with a certificate dated the date of the Transaction

Notice.

(s) On the date hereof

and each Bringdown Date, the Company shall furnish to the Agent a certificate from the Company’s corporate secretary, dated as of

a date within seven (7) days after the applicable Bringdown Date and addressed to the Agent, certifying: (i) that each of the

articles of incorporation and bylaws of the Company is true and complete, has not been modified and is in full force and effect; (ii) that

the resolutions of the Company’s Board of Directors relating to the Offering are in full force and effect and have not been modified;

(iii) the good standing of the Company; and (iv) as to the incumbency of the officers of the Company. The documents referred

to in such certificate shall be attached to such certificate.

(t) On the date hereof

and each Bringdown Date, the Company shall furnish to the Agent a certificate from the Company’s Chief Financial Officer certificate,

dated as of a date within seven (7) days after the applicable Bringdown Date and addressed to the Agent, with respect to certain

financial information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus, in form and substance reasonably

satisfactory to the Agent.

22

(u) A reasonable time

prior to each Bringdown Date, the Company, if so requested by the Agent, shall conduct a due diligence session, in form and substance,

satisfactory to the Agent, which shall include representatives of the management and the accountants of the Company.

(v) The Company shall

disclose in its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q with quarterly financial information the number

of Shares sold through the Agent or any of its designees under this Agreement, the Net Proceeds to the Company and the compensation paid

by the Company with respect to sales of the Shares pursuant to this Agreement.

(w) The Company shall

ensure that there are at all times sufficient Common Stock to provide for the issuance, free of any preemptive rights, out of its authorized

but unissued Common Stock, of the maximum aggregate number of Shares authorized for issuance by the Company’s board of directors

pursuant to the terms of this Agreement. The Company will use its reasonable best efforts to cause the Shares to be listed on Nasdaq,

and to maintain such listing. The Company shall cooperate with the Agent and any of its designees and use its reasonable efforts to permit

Shares to be eligible for clearance and settlement through the facilities of DTC.

(x) At any time during

the term of this Agreement, the Company will advise the Agent promptly after it receives notice or obtains knowledge of any information

or fact that would alter or affect any opinion, certificate, letter and other document provided to the Agent pursuant to Section 3

herein.

(y) Subject to compliance

with any applicable requirements of Regulation M under the Exchange Act and compliance with applicable securities laws, the Company consents

to the Agent and each of its designees trading in Common Stock for the Agent’s and such designee’s own account and for the

account of its respective clients (in compliance with all applicable laws) at the same time as sales of the Shares occur pursuant to this

Agreement.

(z) If to the knowledge

of the Company, any condition set forth in Section 4 of this Agreement shall not have been satisfied on the applicable Settlement

Date or will not be satisfied on or prior to the date required by this Agreement, the Company will offer to any person who has agreed

to purchase the Shares on such Settlement Date from the Company as the result of an offer to purchase solicited by the Agent or any of

its designees the right to refuse to purchase and pay for such Shares.

(aa) On the date hereof and

each Bringdown Date, the Company shall furnish to the Agent an incumbency certificate, dated as of such date and addressed to Agent, signed

by the secretary of the Company.

(bb) Each issuance of a Transaction

Notice to purchase the Shares hereunder shall be deemed to be an affirmation to the Agent that the representations and warranties of the

Company contained in or made pursuant to this Agreement are true and correct as of the date of such acceptance as though made at and as

of such date, and an undertaking that such representations and warranties will be true and correct as of the Settlement Date for the Shares

relating to such acceptance, as though made at and as of such date (except that such representations and warranties shall be deemed to

relate to the Registration Statement and the Prospectus, as amended and supplemented relating to such Shares).

(cc) The Company shall ensure

that there are at all times sufficient Common Stock to provide for the issuance, free of any preemptive rights, out of its authorized

but unissued Common Stock or Common Stock held in treasury, of the maximum aggregate number of Shares authorized for issuance by the Company’s

board of directors pursuant to the terms of this Agreement.

(dd) During any period when

the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant

to Rule 172, 173 or any similar rule) to be delivered under the Securities Act, the Company will file all documents required to be

filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and the regulations thereunder.

(ff) The Company will apply

the Net Proceeds from the sale of the Shares in the manner set forth in the Prospectus.

23

(gg) To the extent that the

Registration Statement is not available for the sales of the Shares as contemplated by this Agreement, the Company shall file a new registration

statement with respect to any additional shares of Common Stock necessary to complete such sales of the Shares and shall cause such registration

statement to become effective as promptly as practicable. After the effectiveness of any such registration statement, all references to

“Registration Statement” included in this Agreement shall be deemed to include such new registration statement, including

all documents incorporated by reference therein pursuant to Item 12 of Form S-3, and all references to “Base Prospectus”

included in this Agreement shall be deemed to include the final form of prospectus, including all documents incorporated therein by reference,

included in any such registration statement at the time such registration statement became effective.

(hh) The Company will conduct

its affairs in such a manner so as to reasonably ensure that neither it nor its Subsidiaries is or, after giving effect to the offering

and sale of the Shares and the application of proceeds therefrom as described in the Prospectus, will be, an “investment company”

within the meaning of such term under the Investment Company Act of 1940, as amended.

(ii) The Company and

its Subsidiaries will use their reasonable efforts to comply with all effective applicable provisions of the Sarbanes-Oxley Act.

(jj) The Company shall maintain,

at its sole expense, a registrar and transfer agent for the Common Stock.

4. Conditions of Agent’s

Obligations. The obligations of the Agent hereunder are subject to (i) the accuracy of, as of the date hereof, each Bringdown

Date, and each Time of Sale (in each case, as if made at such date), and compliance with, all representations, warranties and agreements

of the Company contained herein, (ii) the performance by the Company of its obligations hereunder and (iii) the following additional

conditions:

(a) If the filing of

the Prospectus, or any amendment or supplement thereto, or any Permitted Free Writing Prospectus, is required under the Securities Act

or the Rules and Regulations, the Company shall have filed the Prospectus (or such amendment or supplement) or such Permitted Free

Writing Prospectus with the Commission in the manner and within the time period so required (without reliance on Rule 424(b)(8) or

Rule 164(b)); the Registration Statement shall remain effective; no stop order suspending the effectiveness of the Registration Statement

or any part thereof, any Rule 462(b) Registration Statement, or any amendment thereof, nor suspending or preventing the use

of the Base Prospectus, Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus shall have been issued; no proceedings

for the issuance of such an order shall have been initiated or threatened; and any request of the Commission for additional information

(to be included in the Registration Statement, the Base Prospectus, Prospectus Supplement, the Prospectus, any Permitted Free Writing

Prospectus or otherwise) shall have been complied with to the Agent’s satisfaction.

(b) The Agent shall not

have advised the Company that the Registration Statement, the Base Prospectus, Prospectus Supplement, the Prospectus, or any amendment

or supplement thereto, or any Permitted Free Writing Prospectus, contains an untrue statement of fact which, in the Agent’s opinion,

is material, or omits to state a fact which, in the Agent’s opinion, is material and is required to be stated therein or is necessary

to make the statements therein (i) with respect to the Registration Statement, not misleading and (ii) with respect to the Base

Prospectus, Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus, in light of the circumstances under which

they were made, not misleading.

(c) Except as set forth

or contemplated in the Base Prospectus, Prospectus Supplement, the Prospectus and any Permitted Free Writing Prospectus, subsequent to

the respective dates as of which information is given therein, the Company shall not have incurred any material liabilities or obligations,

direct or contingent, or entered into any material transactions, or declared or paid any dividends or made any distribution of any kind

with respect to its capital stock other than monthly cash dividends on its Series A Convertible Preferred Stock, and there shall

not have been any change in the capital stock, or any issuance of options, warrants, convertible securities or other rights to purchase

the capital stock (other than as a result of the exercise of any currently outstanding stock options, restricted stock units or warrants

that are disclosed in the Prospectus), or any material change in the short-term or long-term debt, of the Company, or any Material Adverse

Effect or any development that would be reasonably likely to result in a Material Adverse Effect (whether or not arising in the ordinary

course of business), or any material loss by strike, fire, flood, earthquake, epidemic, pandemic, accident or other calamity, whether

or not covered by insurance, incurred by the Company, the effect of which, in any such case described above, in the Agent’s judgment,

makes it impractical or inadvisable to offer or deliver the Shares.

24

(d) The Company shall

have performed each of its obligations under Section 3(p).

(e) The Company shall

have performed each of its obligations under Section 3(q).

(f) The Company shall

have performed each of its obligations under Sections 3(r), (s), (t) and (u).

(g) FINRA shall not have

raised any objection to the fairness and reasonableness of the terms and arrangements under this Agreement.

(h) All filings with

the Commission required by Rule 424 under the Securities Act to have been filed by the Settlement Date shall have been made within

the applicable time period prescribed for such filing by Rule 424.

(i) The Company shall

have furnished to Agent and the Agent’s counsel such additional documents, certificates and evidence as they may have reasonably

requested.

(j) Trading in the Common

Stock shall not have been suspended on Nasdaq. The Shares shall have been listed and authorized for trading on Nasdaq prior to the first

Settlement Date, and satisfactory evidence of such actions shall have been provided to the Agent and its counsel, which may include oral

confirmation from a representative of Nasdaq.

(k) The Company shall

have in place a directors and officers insurance policy, in form and substance reasonably satisfactory to Agent.

All such opinions, certificates,

letters and other documents will be in compliance with the provisions hereof only if they are reasonably satisfactory in form and substance

to Agent and the Agent’s counsel. The Company will furnish Agent with such conformed copies of such opinions, certificates, letters

and other documents as Agent shall reasonably request.

5. Indemnification and

Contribution.

(a) (i) The Company

agrees to indemnify and hold harmless the Agent and each of the other Indemnified Parties (as defined below) from and against, and pay

on demand for, any and all losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses and disbursements,

and any and all actions, suits, proceedings and investigations in respect thereof and any and all legal and other costs, expenses and

disbursements in giving testimony or furnishing documents in response to subpoena or otherwise (including, without limitation, the costs,

expenses and disbursements, as and when incurred, of investigating, preparing, pursuing or defending any such action, suit, proceeding

or investigation (whether or not in connection with litigation in which any Indemnified Party is a party)) (collectively, “Losses”),

directly or indirectly, caused by, relating to, based upon, arising out of, or in connection with this Agreement, including, without limitation,

any act or omission by the Agent in connection with its acceptance of or the performance or non-performance of its obligations under the

Agreement, any and all Losses as incurred arising out of or based upon any untrue statement of a material fact contained in the Registration

Statement (or any amendment thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or

necessary to make the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material

fact included in any related Permitted Free Writing Prospectus, the Base Prospectus, any Prospectus Supplement and the Prospectus (or

any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the

statements therein, in the light of the circumstances under which they were made, not misleading, any breach by the Company of any representation,

warranty, covenant or agreement contained in the Agreement (or in any instrument, document or agreement relating thereto, including any

agency agreement), or the enforcement by the Agent of its rights under the Agreement or these indemnification provisions, except to the

extent that any such Losses are found in a final judgment by a court of competent jurisdiction (not subject to further appeal) to have

resulted primarily and directly from the gross negligence or willful misconduct of the Indemnified Party seeking indemnification hereunder.

The Company also agrees that no Indemnified Party shall have any liability (whether direct or indirect, in contract or tort or otherwise)

to the Company for or in connection with this Agreement for any other reason, except to the extent that any such liability is found in

a final judgment by a court of competent jurisdiction (not subject to further appeal) to have resulted primarily and directly from such

Indemnified Party’s gross negligence or willful misconduct This indemnity agreement will be in addition to any liability that the

Company otherwise might have.

25

(ii) These indemnification

provisions shall extend to the following persons (collectively, the “Indemnified Parties”): the Agent, its present

and former affiliates, managers, members, officers, employees, legal counsel, agents and controlling persons (within the meaning of Section 15

of the Securities Act and Section 20 of the Exchange Act), each of the Agent’s designees utilized by the Agent in connection

with this Offering, and the officers, directors, partners, stockholders, members, managers, employees, legal counsel, agents and controlling

persons of any of them. These indemnification provisions shall be in addition to any liability which the Company may otherwise have to

any Indemnified Party.

(iii) If any action,

suit, proceeding or investigation is commenced, as to which an Indemnified Party proposes to demand indemnification, it shall notify the

Company with reasonable promptness; provided, however, that any failure by an Indemnified Party to notify the Company shall

not relieve the Company from its obligations hereunder except to the extent that the Company is actually and materially prejudiced by

such failure to notify. An Indemnified Party shall have the right to retain counsel of its own choice to represent it, and the fees, expenses

and disbursements of such counsel shall be borne by the Company. Any such counsel shall, to the extent consistent with its professional

responsibilities, cooperate with the Company and any counsel designated by the Company. The Company shall be liable for any settlement

of any claim against any Indemnified Party made with the Company’s written consent. The Company shall not, without the prior written

consent of the Agent, settle or compromise any claim, or permit a default or consent to the entry of any judgment in respect thereof,

unless such settlement, compromise or consent (i) includes, as an unconditional term thereof, the giving by the claimant to all of

the Indemnified Parties of an unconditional release from all liability in respect of such claim, and (ii) does not contain any factual

or legal admission by or with respect to an Indemnified Party or an adverse statement with respect to the character, professionalism,

expertise or reputation of any Indemnified Party or any action or inaction of any Indemnified Party.

(iv) In order to provide

for just and equitable contribution, if a claim for indemnification pursuant to these indemnification provisions is made but it is found

in a final judgment by a court of competent jurisdiction (not subject to further appeal) that such indemnification may not be enforced

in such case, even though the express provisions hereof provide for indemnification in such case, then the Company shall contribute to

the Losses to which any Indemnified Party may be subject (i) in accordance with the relative benefits received by the Company and

its stockholders, subsidiaries and affiliates, on the one hand, and the Indemnified Party, on the other hand, and (ii) if (and only

if) the allocation provided in clause (i) of this sentence is not permitted by applicable law, in such proportion as to reflect not

only the relative benefits, but also the relative fault of the Company, on the one hand, and the Indemnified Party, on the other hand,

in connection with the statements, acts or omissions which resulted in such Losses as well as any relevant equitable considerations. No

person found liable for a fraudulent misrepresentation shall be entitled to contribution from any person who is not also found liable

for fraudulent misrepresentation. The relative benefits received (or anticipated to be received) by the Company and its stockholders,

subsidiaries and affiliates shall be deemed to be equal to the aggregate consideration payable or receivable by such parties in connection

with the transaction or transactions to which the Agreement relates relative to the amount of fees actually received by the Agent in connection

with such transaction or transactions. Notwithstanding the foregoing, in no event shall the amount contributed by all Indemnified Parties

exceed the amount of fees previously received by the Agent pursuant to the Agreement.

(b) (i) The Agent

will indemnify and hold harmless the Company and its affiliates, employees, and directors and each officer of the Company who signed the

Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or

Section 20 of the Exchange Act and controlling persons of any of them (the “Company Indemnified Parties”)

from and against any Losses to which the Company or the Company Indemnified Parties may become subject, under the Securities Act or otherwise

(including in settlement of any litigation, if such settlement is effected with the written consent of the Agent), insofar as such losses,

claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or omission or alleged

untrue statement or omission of a material fact contained in the Registration Statement, any Base Prospectus, Prospectus Supplement, the

Prospectus, or any amendment or supplement thereto or any Permitted Free Writing Prospectus, but only and solely to the extent that such

untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any Base Prospectus,

Prospectus Supplement, the Prospectus, or any amendment or supplement thereto, or any Permitted Free Writing Prospectus in reliance upon

and in conformity with written information furnished to the Company by Agent expressly for use in the preparation thereof, it being understood

and agreed that the only information furnished by the Agent consists of the information described as such in Section 5(b)(ii) hereof,

by the Company in connection with investigating or defending against any such loss, claim, damage, liability or action.

26

(ii) The Agent confirms

and the Company acknowledges that as of the date hereof no information has been furnished in writing to the Company by or on behalf of

the Agent specifically for inclusion in the Registration Statement, any Base Prospectus, Prospectus Supplement, the Prospectus or any

Permitted Free Writing Prospectus.

(c) If the indemnification

provided for in this Section 5 is unavailable or insufficient to hold harmless an indemnified party under subsection (a) or

(b) above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the

losses, claims, damages or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate

to reflect the relative benefits received by the Company on the one hand and the Agent on the other from the Offering or (ii) if

the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not

only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and the Agent

on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any

other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Agent on the other shall

be deemed to be in the same proportion as the total net proceeds from the Offering (before deducting expenses) received by the Company

and the total commissions received by the Agent from the sale of the Shares. The relative fault shall be determined by reference to, among

other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material

fact relates to information supplied by the Company or the Agent and the parties’ relevant intent, knowledge, access to information

and opportunity to correct or prevent such untrue statement or omission. The Company and the Agent agree that it would not be just and

equitable if contributions pursuant to this subsection (c) were to be determined by pro rata allocation or by any other method of

allocation which does not take account of the equitable considerations referred to in the first sentence of this subsection (c). The amount

paid by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this subsection

(c) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating

or defending against any action or claim which is the subject of this subsection (c). Notwithstanding the provisions of this subsection

(c), an Indemnified Party shall not be required to contribute any amount in excess of the amount by which the total price at which the

Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such Indemnified

Party has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person

guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution

from any person who was not guilty of such fraudulent misrepresentation.

(d) Neither termination

of this Agreement nor completion of the Offering shall affect these indemnification provisions, which shall remain operative and in full

force and effect. The indemnification provisions shall be binding upon the Company and the Agent and their respective successors and assigns

and shall inure to the benefit of the Indemnified Parties and the Company Indemnified Parties and their respective successors, assigns,

heirs and personal representatives.

6. Representations and

Agreements to Survive Delivery. All representations and warranties of the Company herein or in certificates delivered pursuant

hereto, and agreements of the Agent and the Company herein, including but not limited to the agreements of the Agent and the Company contained

in Section 5 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf

of the Agent or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons, and shall survive

delivery of, and payment for, the Shares to and by the Agent or any of its designees hereunder.

7. Termination of this

Agreement.

(a) The Company shall

have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating to the solicitation

of offers to purchase the Shares in its sole discretion at any time upon ten (10) days’ prior written notice. Any such termination

shall be without liability of any party to any other party except that (i) if the Shares have been sold through the Agent or any

of its designees for the Company, then Sections 3(g), 3(o) and 3(y) shall remain in full force and effect,

(ii) with respect to any pending sale, through the Agent or any of its designees for the Company, the obligations of the Company

with respect to such pending sale of Shares, including in respect of compensation of the Agent, shall remain in full force and effect

notwithstanding such termination and (iii) the provisions of Section 2(a)(vi), Section 3(g), Section 3(o),

Section 5 and Section 6 of this Agreement shall remain in full force and effect notwithstanding such termination.

27

(b) The Agent shall have

the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating to the solicitation

of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability of any party to any

other party except that (i) the provisions of the last three sentences Section 3(g) and the entirety of Section 3(o),

Section 5 and Section 6 of this Agreement shall remain in full force and effect notwithstanding such termination

and (ii) the provisions of Section 3(g) other than the last three sentences thereof shall remain in full force and

effect only if the Agent has terminated this Agreement as a result of the Company’s default of its obligations hereunder and its

failure to cure any default within a reasonable period of time.

(c) This Agreement shall

remain in full force and effect for twelve (12) months from the date hereof, by and between the Company and the Agent, unless terminated

pursuant to Sections 7(a) or (b) above or otherwise by mutual agreement of the parties; provided that any such

termination by mutual agreement shall in all cases be deemed to provide that Section 3(g), Section 3(o), Section 5

and Section 6 shall remain in full force and effect. This Agreement shall terminate automatically upon the issuance and sale

of Shares having an aggregate offering price equal to the amount set forth in the first paragraph of this Agreement.

(d) Any termination of

this Agreement shall be effective on the date specified in such notice of termination; provided that such termination shall not be effective

until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination

shall occur prior to the Settlement Date for any sale of the Shares, such sale shall settle in accordance with the provisions of Section 2(a) of

this Agreement.

8. Default by the Company.

If the Company shall fail at any Settlement Date to sell and deliver the number of Shares which it is obligated to sell hereunder, then

the Company shall have five (5) business days to cure such default and deliver such Shares. No action taken pursuant to this Section 8

shall relieve the Company from liability, if any, in respect of such default, and the Company shall (A) hold the Agent or any of

its designees harmless against any loss, claim or damage arising from or as a result of such default by the Company and (B) pay the

Agent any commission to which it would otherwise be entitled absent such default.

9. Notices.

Except as otherwise provided herein, all communications under this Agreement shall be in writing and, if to the Agent, shall be mailed,

delivered or sent by email transmission to A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022,

Attention: [•] (email: [•])

or at such other address and/or contact information which may be furnished by A.G.P./Alliance Global Partners to the Company expressly

for such purpose, with a required copy (which shall not constitute notice) to Honigman LLP, 2290 First National Building, 660 Woodward

Ave, Detroit, MI 48226, Attention: Michael J. Rosenberg, Esq. (email: mrosenberg@honigman.com). Notices to the Company shall be given

to it at 48389 Fremont Boulevard, Suite 110, Fremont, CA 94538, Attention: Steven N. Bronson, Chief Executive Officer (email: sb@iefsr.com,

with a required copy (which shall not constitute notice) to Stubbs Alderton & Markiles, LLP, 15260 Ventura Boulevard, 21st

Floor, Sherman Oaks, CA 91403, Attn: John J. McIlvery, Esq. (email: jmcilvery@stubbsalderton.com). Any party to this Agreement may

change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.

10. Persons Entitled

to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective

successors and assigns and the controlling persons, officers and directors referred to in Section 5. Nothing in this Agreement

is intended or shall be construed to give to any other person, firm or corporation any legal or equitable remedy or claim under or in

respect of this Agreement or any provision herein contained. The term “successors and assigns” as herein used shall not include

any purchaser, as such purchaser, of any of the Shares from the Agent or any of its designees.

11. Absence of Fiduciary

Relationship. The Company acknowledges and agrees that: (a) the Agent has been retained solely to act as an sales agent and/or

principal in connection with the sale of the Shares and that no fiduciary, advisory or agency relationship between the Company and the

Agent or any of its designees has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether

the Agent or any of its designees have advised or are advising the Company on other matters; (b) the price and other terms of the

Shares set forth in this Agreement were established by the Company following discussions and arms-length negotiations with the Agent and

the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions

contemplated by this Agreement; (c) the Company has been advised that the Agent and its affiliates and such other designees are engaged

in a broad range of transactions which may involve interests that differ from those of the Company and that the Agent and such other parties

have no obligation to disclose such interest and transactions to the Company by virtue of any fiduciary, advisory or agency relationship;

(d) the Company has been advised that the Agent and such other designees are acting, in respect of the transactions contemplated

by this Agreement, solely for the benefit of the Agent and such other parties, and not on behalf of the Company; and (e) the Company

waives to the fullest extent permitted by law, any claims it may have against the Agent and any of its affiliates, and other designees

for breach of fiduciary duty or alleged breach of fiduciary duty in respect of any of the transactions contemplated by this Agreement

and agrees that the Agent and such other parties shall have no liability (whether direct or indirect) to the Company in respect of such

a fiduciary duty claim on behalf of or in right of the Company, including stockholders, employees or creditors of the Company.

28

12. Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including Section 5-1401

of the General Obligations Law of the State of New York, but otherwise without regard to conflict of laws rules that would apply

the laws of any other jurisdiction.

13. Counterparts.

This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall

each be deemed to be an original and all such counterparts shall together constitute one and the same instrument. In the event that any

signature is delivered by facsimile transmission or a .pdf or other electronic format file, such signature shall create a valid and binding

obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile

or .pdf or other electronic signature page were an original thereof.

14. Adjustments for

Stock Splits. The parties hereto acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted

to take into account any stock split, stock dividend or similar event effected by the Company with respect to the Shares.

15. Entire Agreement;

Amendment; Severability; Headings. This Agreement (including all schedules and exhibits attached hereto and transaction notices

issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,

both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may

be waived or amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one or more

of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written

by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it

is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or

unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder

of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. The section headings

used in this Agreement are for convenience only and shall not affect the construction hereof.

16. Waiver of Jury Trial.

Each of the Company and the Agent hereby waives any right it may have to a trial by jury in respect of any claim based upon or arising

out of this Agreement or the transactions contemplated hereby.

17. Submission to Jurisdiction.

The Company irrevocably submits to the non-exclusive jurisdiction of any New York State or United States federal court sitting in The

City of New York, Borough of Manhattan, over any suit, action or proceeding arising out of or relating to this Agreement, the Prospectus,

the Registration Statement, or the offering of the Shares. The Company irrevocably waives, to the fullest extent permitted by law, any

objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding brought in such a court and

any claim that any such suit, action or proceeding brought in such a court has been brought in an inconvenient forum. To the extent that

the Company has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court

or from any legal process with respect to itself or its property, the Company irrevocably waives, to the fullest extent permitted by law,

such immunity in respect of any such suit, action or proceeding including without limitation, any immunity pursuant to the U.S. Foreign

Sovereign Immunities Act of 1976, as amended. Each of the Agent and the Company further agrees to accept and acknowledge service of any

and all process which may be served in any such suit, action or proceeding in the Supreme Court of the State of New York, New York County,

or in the United States District Court for the Southern District of New York and agrees that service of process upon the Company mailed

by certified mail or delivered by Federal Express via overnight delivery to the Company’s address shall be deemed in every respect

effective service of process upon the Company in any such suit, action or proceeding, and service of process upon the Agent mailed by

certified mail or delivered by Federal Express via overnight delivery to the Agent’s address shall be deemed in every respect effective

service of process upon such Agent in any such suit, action or proceeding.

[Signature Page Follows]

29

If the foregoing is in accordance

with your understanding of our agreement, please sign and return to the Company the enclosed duplicate of this At-The-Market Issuance

Sales Agreement, whereupon this letter and your acceptance shall represent a binding agreement between the Company and the Agent in accordance

with its terms.

Very truly yours,

Interlink Electronics, Inc.

By:

/s/ Steven N. Bronson

Name:

Steven N. Bronson

Title:

Chief Executive Officer and President

Confirmed as of the date first above mentioned.

A.G.P./Alliance Global Partners As Agent

By:

/s/ Thomas J. Higgins

Name:

Thomas J. Higgins

Title:

Managing Director

[Signature Page to At-The-Market Issuance

Sales Agreement]

30

Schedule A

Permitted Free Writing Prospectus

None.

31

Schedule B

Individuals Permitted to Authorize Sales of Shares

by Transaction Notice

Interlink Electronics, Inc.:

Steven N. Bronson

Chief Executive Officer, President and Chairman of the Board of Directors

Cell: (805) 551-3661

Office: (949) 504-4442

Email: sb@iefsr.com

Ryan J. Hoffman

Chief Financial Officer and Secretary

Cell: (714) 809-9821

Office: (949) 504-4454

Email: rhoffman@iefsr.com

32

Schedule C

Form of Transaction Notice

From:

Interlink Electronics, Inc.

To:

A.G.P./Alliance Global Partners

Subject:

Transaction Notice

Date:

[●], 202[_]_

Ladies and Gentlemen:

Pursuant to the terms and

subject to the conditions contained in the At-The-Market Issuance Sales Agreement between Interlink Electronics, Inc. (the “Company”),

and A.G.P./Alliance Global Partners (“Agent”), dated [·], 2026,

the Company hereby requests that the Agent sell up to [__] of the Company’s common stock, par value $0.001 per share, at a minimum

market price of $[__] per share, during the time period beginning [month, day, time] and ending [month, day, time].

The Company hereby [authorizes]

[does not authorize] the Agent to sell Shares during pre-market and post-market trading sessions (including, without limitation, sales

made outside regular trading hours on Nasdaq or any other trading market for the Common Stock) during the time period set forth above.

33

Schedule D

Individuals to Whom a Transaction Notice Can Be

Given

A.G.P./Alliance Global Partners:

●

[·]

Address: [·]

Email: [·]

●

[·]

Address: [·]

Email: [·]

●

[·]

Address: [·]

Email: [·]

●

[·]

Address: [·]

Email:

[·]

34

EX-5.1 — EXHIBIT 5.1

EX-5.1

Filename: tm2629702d1_ex5-1.htm · Sequence: 3

Exhibit 5.1

November 13, 2026

Interlink Electronics, Inc.

48389 Fremont Boulevard, Suite 110

Fremont, California 94538

Ladies and Gentlemen:

We have acted as counsel to Interlink Electronics, Inc.,

a Nevada corporation (the “Company”) in connection with the offering by the Company of shares of the Company’s

common stock, par value $0.001 per share, with an aggregate offering price of up to $7,200,000 (the “Shares”), pursuant

to (i) a Registration Statement on Form S-3 (File No. 333-283879) (the “Registration Statement”), filed

with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities

Act”), (ii) the prospectus included within the Registration Statement (the “Base Prospectus”), and (iii) the

prospectus supplement dated November 13, 2026, filed with the Commission pursuant to Rule 424(b) of the Rules and

Regulations of the Securities Act (together with the Base Prospectus, the “Prospectus”).

The Shares are to be sold by the Company as described

in the Prospectus and in accordance with the At-The-Market Issuance Sales Agreement, dated November 13, 2026, between the Company

and A.G.P/Alliance Global Partners (the “Sales Agreement”).

In connection with this opinion, we have examined

and relied upon (a) the Registration Statements and the Prospectus, (b) the Company’s Articles of Incorporation and By-laws,

each as amended and currently in effect, (c) the Sales Agreement, and (d) the originals, or copies certified to our satisfaction,

of such records, documents, certificates, opinions, memoranda and other instruments as in our judgment are necessary or appropriate to

enable us to render the opinion expressed below. As to certain factual matters, we have relied upon certificates of the officers of the

Company and have not independently sought to verify such matters.

In rendering this opinion, we have assumed the

genuineness and authenticity of all signatures on original documents; the authenticity of all documents submitted to us as originals;

the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of

public officials; and the due authorization, execution and delivery of all documents where authorization, execution and delivery are prerequisites

to the effectiveness of such documents.

We have assumed (i) that the specific sale

of Shares will be duly authorized by the Board of Directors of the Company in accordance with Chapter 78 of the Nevada Revised Statutes

(the “NRS”) and (ii) that no more than 7,200,000 Shares will be sold.

Our opinion herein is expressed solely with respect

to the federal laws of the United States and the NRS. Our opinion is based on these laws as in effect on the date hereof. We express no

opinion as to whether the laws of any jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to

compliance with any federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof.

15260 Ventura Boulevard, 21st Floor * Sherman Oaks, California 91403

office > 818.444.4500 * fax > 818.444.4520

Interlink Electronics, Inc.

November 13,

2026

Page 2

On the basis of the foregoing and in reliance thereon,

and subject to the qualifications herein stated, we are of the opinion that the Shares have been duly authorized for issuance and, when

issued and paid for in accordance with the terms and conditions of the Sales Agreement, the Shares will be validly issued, fully paid

and nonassessable.

It is understood that this opinion is to be used

only in connection with the offer and sale of the Shares while the Registration Statement is in effect and may not be used, quoted or

relied upon for any other purpose nor may this opinion be furnished to, quoted to or relied upon by any other person or entity, for any

purpose, without our prior written consent.

We hereby consent to the filing of this opinion

in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act with the Commission as an exhibit

to the Current Report on Form 8-K to be filed by the Company in connection with the issue and sale of the Shares and to the use of

our name in the Prospectus under the caption “Legal Matters.”

Sincerely,

/s/ Stubbs Alderton & Markiles,

LLP

Stubbs Alderton & Markiles,

LLP

GRAPHIC

GRAPHIC

Filename: tm2629702d1_ex5-1img01.jpg · Sequence: 7

Binary file (11430 bytes)

Download tm2629702d1_ex5-1img01.jpg

GRAPHIC

GRAPHIC

Filename: tm2629702d1_ex5-1img02.jpg · Sequence: 8

Binary file (1303 bytes)

Download tm2629702d1_ex5-1img02.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 10

v3.26.3

Cover

Nov. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Nov. 13, 2026

Entity File Number

001-37659

Entity Registrant Name

INTERLINK ELECTRONICS, INC.

Entity Central Index Key

0000828146

Entity Tax Identification Number

77-0056625

Entity Incorporation, State or Country Code

NV

Entity Address, Address Line One

48389 Fremont Boulevard

Entity Address, Address Line Two

Suite 110

Entity Address, City or Town

Fremont

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

94538

City Area Code

510

Local Phone Number

244-0424

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

LINK

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration